TITLE OF THE INVENTION

Closed-Loop Multi-Analyte Patient Homeostasis System

DESCRIPTION

§2 System-Level Overview

(FIG-1 shows the block diagram.)



External device links: RS-485 or CAN to CRRT console, ventilator, cooling blanket.
Power: 7.4 V 2 Ah Li-poly – ≥24 h at 600 mWh duty; hot-swap DC barrel for longer use.

---

§3 Sensor Suite

Module	Form-factor	Channel count	Key analytes	Wear-life	Skin area / line
S-Patch-X	45 mm sweat, parylene-PEGMA	24	Na, K, Cl, Ca, Mg, Zn, Cu, PO_4, lactate, glucose, ROS, NOx, heavy metals	48 h	16 cm^2
S-Patch-G	35 mm sweat LFA	5	SARS-CoV-2, Influenza A/B, RSV F-Ag, Endotoxin LPS	12 h	10 cm^2
MN-Array Ω	1 × 1 cm dissolvable MN	38	IL-1β, IL-6, IL-8, IL-10, TNF-α, HMGB-1, etc.	24 h	1 cm^2
MN-Array-Drug	1 × 1 cm MN	14	Vancomycin, DOACs, MTX, etc.	48 h	1 cm^2
Arterial-Line chip	Inline 4 Fr	10	Anti-Xa, INR, Hb/Hct, COHb, 2,3-DPG	5 d	—
Dialysate cartridge	Clip-on CRRT	12	NGAL, Cys-C, cfDNA, β-D-Glucan, drug levels	72 h	—
Neuro bolt & MD	Licox + catheter	3	ICP, $PbtO_2$, brain glucose	5 d	—
Vent-gas pod	Y-piece	6	$ETCO_2$, pO_2, Isoflurane %, VOC slot	5 d	—

Module	Form-factor	Channel count	Key analytes	Wear-life	Skin area / line
Others (NIRS, BIS, TOF, Esoph VO_2, Gastric $PgCO_2$)	–	8	rSO_2, BIS, TOF ratio, VO_2/VCO_2	24–72 h	28 cm^2 combined

Total occupied skin: ≈ 56 cm^2 (< half an adult palm).

---

§4 Therapeutic & Actuator Suite

Bay	Capacity (default)	Payload examples
MicroDose-4X (1-4)	4 × 5 mL syringes	Zn/Cu, Ca/Mg, insulin/dextrose, NaCl or 3 %
PumpFlex (5-16)	12 smart pumps	Tocilizumab, Etanercept, NAC, DDAVP, Echinocandin, Methylene Blue
Antidote bays (37-46)	10	$CaNa_2$-EDTA, Digibind, Hydroxocobalamin, Pralidoxime, Fomepizole
External links	RS-485 / CAN	Dialysis bath command, ventilator FiO_2, cooling blanket

Each cartridge stores **drug class, molarity, and daily mg kg^{-1} limit** in EEPROM; pumps contain SLF3x flow-sensors (±5 %).

---

§5 Control Software & Decision Logic

5.1 Signal pathway

1. Raw sensor vector → median + Kalman filter.
2. Adaptive calibration matrix converts sweat/interstitial values to serum estimates (recursive least squares; updates on each lab result).

5.2 Three-layer arbiter

Layer	Latency	Function
L-0 Vital Override	≤ 5 s	Stops offending infusions; fires antidotes; commands vent/CRRT.
L-1 Guard-Rail Balancer	≤ 30 s	Solves quadratic constraints to maintain ratios (Zn:Cu ≤ 50 etc.); applies knock-down rules.
L-2 Optimiser / Steward	≤ 5 min	PID or MPC drives biomarkers to clinician-set targets; nutrition & antibiotic stewardship.

5.3 Conflict-graph knock-down

Higher-priority actions can suppress lower by consulting a directed graph (e.g., protamine blocks vancomycin; insulin halves if $K^+ < 3.5$).

5.4 Pseudocode excerpt (best-mode)

```
for layer in (L0, L1, L2):
    for rule in queue[layer]:
        if not conflicts(rule, executed):
            run(rule); executed.add(rule)
```

[Insert Tables 5-B to 5-H and the Knock-Down Matrix at this point.]

§6 Safety & Fail-safes

- Redundant sensor channels; disagreement > 10 % → maintenance-drip fallback.
- Dose-budget watchdog forecasts 30 min ahead to pre-block ceiling breaches.
- Two optical bubble sensors plus pressure break detect line occlusion.
- Cartridges with wrong EEPROM class code cannot energise.
- OTA firmware uses signed image, validated at boot (FIPS 140-3).

§7 Hardware & Power

- **Controller PCB:** 4 × ADuCM355, nRF52840, 24-bit isolated ADC, dual 5 V boost, hot-swap gauge.
- **Pump cradle:** CAN-bus backplane, 2.54 mm pogo pins, PEEK wet-parts, autoclavable shell.
- **Battery:** 2 Ah Li-poly; 600 mWh duty → 24 h; recharge via USB-C PD 15 W.

§8 Materials & Manufacturing

Layer	Material	Process
Electrode	LIG graphene on 75 µm PI	10 W CO_2 laser, 8 kHz scan
Seed layer	80 nm Au	Sputter, 10^{-6} mbar
Insulation	8 µm parylene-C	Chemical vapor deposition
Collector	PEGMA graft 60 s plasma	–
Adhesive	MED-5630 hydrocolloid 42 µm	Rotary die-lamination
Microneedle tips	PVA/trehalose with aptamer inks	Room-temp molding, γ-sterile

§9 Performance Benchmarks

Parameter	Spec
Electrolyte accuracy	±3 % vs venous lab, 48 h
Cytokine SNR	> 10 at 30 pg mL^{-1}
Pump precision	±5 %, 0.5–1200 µL h^{-1}
Closed-loop latency	L-0 ≤ 5 s; L-1 ≤ 30 s; L-2 ≤ 5 min

Parameter	Spec
BLE range	≥ 10 m LOS
Adhesion peel	≥ 1 N cm^{-1} to 48 h
Battery life	≥ 24 h at 600 mWh

§10 Clinical Consumable Cadence

Consumable	Swap interval	Reason
S-Patch-G (LFA)	12 h	Conjugate pad desiccation
Microneedle Ω	24 h	Aptamer fouling
S-Patch-X	48 h	Adhesive peel & ASV drift
Drug MN array	48 h	Enzyme half-life
NIRS gel	72 h	Optical clarity
Arterial chip tubing	5 d	Standard line change
Dialysate sensor cassette	72 h	Filter swap alignment

§11 Development & Regulatory Roadmap

Phase	Key deliverable	Months (from Q3-2025)
0 Feasibility	Bench proof (ISE + mp6)	0–6
1 Alpha	Wearable 7-ion + IL-6 prototype	6–18
2 GLP	Large-animal endotoxin & mineral models	18–30
3 Human IDE	15-pt ICU pilot	30–42
4 RCT	400-pt multicentre trial	42–66
5 Reg	FDA De Novo + EU MDR	66–78

Compliance: IEC 60601-1-10, ISO 10993, ISO 14971, FDA AI/ML PCCP.

§12 Regulatory Classification

Combination product: externally-powered infusion device + diagnostic software.
Expected classification: **FDA De Novo, Class II** (special controls for multi-analyte closed-loop), EU MDR **Class IIb.**

§13 Appendices

- **Appendix A** – *Matrix tables 5-B to 5-H (140 loops).*
- **Appendix B** – *Full knock-down interaction matrix.*
- **Appendix C** – *Bench and porcine validation data.*
- **Appendix D** – *Gantt chart & budget worksheet.*

Annex E Sequence Listing Placeholder (ST.26)

```
<Sequence>
  <SequenceID>1</SequenceID>
  <SequenceName>IL6_Aptamer_V1</SequenceName>
  <SequenceResidues>GGCAGGACACGAC...</SequenceResidues>
</Sequence>
…
```

Annex F Alternative Embodiments

1. Optical K$^+$ crown-ether fluorimeter in place of ISE, etc.
2. Three-roller peristaltic cassette in place of mp6 diaphragm pumps.
3. Paper-fluidic IL-6 strip with smartphone readout.
4. Li-ion 18650 hot-swap battery sled.
5. LoRaWAN long-range telemetry mode.

Annex G Best-Mode Firmware Snippet

```
for layer in (L0, L1, L2):
   for rule in queue[layer]:
      if not conflicts(rule, executed):
         run(rule)
```

Annex H Numeric Material Ranges

Parameter	Best-mode	Claimed range
Parylene thickness	8 µm	2–20 µm
Bi(NO$_3$)$_3$ bath	1 mM	0.1–10 mM
Microneedle length	600 µm	300–900 µm
Adhesive peel	1.3 N cm^{-1}	0.7–2 N cm^{-1}

Annex I Representative Bench Data

(insert table or plots; sample given earlier)

Annex J Failure-Mode & Fallback Table

Fault	Response	Result
Sensor dropout > 10 min	Maintenance-drip	Safe stasis
EEPROM mismatch	Pump lockout	Drug mis-load impossible
Flow sensor ±15 %	Rate capped 50 %	Prevents overdose
Battery < 10 %	Monitor-only mode	Safe shutdown

Annex K Manufacturing Flow

1. Screen-print electrodes → IR cure 5 min @ 120 °C
2. Laser-induce graphene, 10 W CO_2, 8 kHz scan
3. Au sputter 80 nm → parylene 8 µm → PEGMA plasma 60 s
4. Laminate hydrocolloid & die-cut; pouch under N_2; γ-sterilise 25 kGy.

Annex L Boiler-Plate "Any Biomarker" Language

"Although 140 exemplar biomarkers are enumerated, any physiologically relevant ion, small molecule, peptide, nucleic acid, pathogen antigen, or gas that can be transduced into an electrical, optical, magnetic, or mass-change signal and correlates to a measurable physiologic or pathologic state is within the term 'analyte' as used herein. All sensor, control, and safety features disclosed apply mutatis mutandis to such analytes."

Annex M Claim Skeleton (informal)

CLAIMS 1. A closed-loop therapeutic system comprising: (a) a sensor array that simultaneously measures at least twenty biochemically distinct analytes in a human patient; (b) a therapeutic actuator assembly including at least five independently addressable reagent cartridges; and (c) a hierarchical arbiter that (i) ranks sensor deviations by harm-severity and time-to-harm, (ii) enforces predefined inter-analyte ratio constraints, and (iii) suppresses or delays any cartridge actuation whose EEPROM-encoded drug-class code conflicts with a drug-class code of a cartridge that is already energised.

1. **System** comprising: (a) multi-analyte sensor array with ≥ 20 distinct channels; (b) multi-channel therapeutic actuator with ≥ 5 infusion channels; (c) hierarchical arbiter enforcing predefined inter-analyte constraints.
2. The system of claim 1 wherein the sensor array is a sweat patch comprising at least five ion-selective electrodes and two anodic-stripping voltammetric electrodes.
3. The system of claim 1 wherein each therapeutic cartridge carries an EEPROM and the arbiter disables energisation upon detection of a conflicting drug-class code.
4. The method of auto-chelating a heavy-metal toxicity by sensing the metal concentration, infusing a chelating agent, and suspending mineral-replacement infusions until the concentration is within target range.

1. A closed-loop therapeutic system comprising: (a) a sensor array that simultaneously measures at least twenty biochemically distinct analytes in a human patient; (b) a therapeutic actuator assembly including at least five independently addressable reagent cartridges; and (c) a hierarchical arbiter that (i) ranks sensor deviations by harm-severity and time-to-harm, (ii) enforces predefined inter-analyte ratio constraints, and (iii) suppresses or delays any cartridge actuation whose EEPROM-encoded drug-class code conflicts with a drug-class code of a cartridge already energised.

End of Specification (matrices to be inserted where noted)

Analyte Class	State Trigger	Primary Closed-Loop Action	Counter-Measure / Extraction Channel	Cross-Factor & Cartridge-Swap Logic
Glucose / Energy	**Hypo-glycaemia** < 100 mg dL^{-1} or ROC < -2 mg dL^{-1} min^{-1}	Stop insulin Pump-2; start D50W bolus Pump-3 (0.5 g kg^{-1} h^{-1})	—	If K^+ also low, controller pauses dextrose once Na:K ≥ 28 to avoid further K^+ drop.
	Hyper-glycaemia > 180 mg dL^{-1} or ROC $> +2$ mg dL^{-1} min^{-1}	PID insulin micro-dose Pump-2 (max 6 U h^{-1})	Option: swap Pump-2 cartridge for rapid-acting insulin if basal is exhausted (UI prompt for nurse).	High glucose auto-enables lactate adsorb column in CRRT if lactate $>$ 3 mmol L^{-1}.
Inflammatory Cytokines	**IL-6 > 50 pg mL^{-1} OR TNF-α > 25 pg mL^{-1}**	Pump-5 tocilizumab or etanercept weight-based bolus; repeat q8h until level < target	Spare Pump-6 holds second monoclonal (e.g. anakinra). System auto-prompts cartridge change if vial empty.	Cytokine storm often raises lactate; mapping engine pre-emptively raises insulin set-point to prevent stress hyper-glycaemia.
	Low cytokine (below detection)	Pause biologic; watchdog prevents	—	If infection marker (procalcitonin)

		<-10 % per day to avoid immunosuppression		rises while cytokines low, controller blocks biologic restart.
Coagulation / Endothelium	**Sub-therapeutic anti-Xa < 0.3 IU mL^{-1}**	Start heparin Pump-3 to 6 U kg^{-1} h^{-1}	—	High fibrinogen > 400 mg dL^{-1} triggers simultaneous low-dose TXA to balance fibrinolysis.
	Anti-Xa > 0.7 IU mL^{-1} or D-dimer surge	Stop heparin; Pump-3 protamine 1 mg per 100 U heparin units; optional AT-III concentrate for deficiency	Dialysis console: switch to heparin-free citrate circuit	Protamine infusion halts if pulmonary pressure sensor in ventilator rises (anaphylaxis guard).
Acid–Base & Gas	**pH < 7.20 or pCO_2 > 60 mm Hg**	Pump-4 $NaHCO_3$ 50 mEq over 30 min; ventilator FiO_2 +5 %	Tromethamine (THAM) cartridge auto-swap if bicarbonate stock empty	Bicarb bolus pauses Ca-Mg infusion 10 min to avoid $CaCO_3$ precipitation.
	Alkalosis pH > 7.55	Halt bicarbonate; ventilator $ETCO_2$ target up by 5 mm Hg	Maintenance fluid switches to 0.45 % saline	If K^+ already low, controller injects KCl to limit alkalosis-driven K shift.
Renal-Injury Markers	**NGAL or KIM-1 rise > 2× baseline**	CRRT effluent rate +25 %; reduce nephrotoxic antibiotic pump by 30 %	—	Rising NGAL auto-reduces Zn dosing (Zn cleared renally) to prevent accumulation.
Drug PK (Vancomycin et al.)	**Trough < 10 µg mL^{-1}**	Smart syringe titrates next dose ↑ 25 %	—	High NGAL prompts algorithm to widen dosing interval even if trough low.
	Trough > 20 µg mL^{-1}	Hold next dose; if ROC ↑, Pump-5 starts fosfomycin (alternate antibiotic)	If CRRT on, column flow ↑ to remove drug	Controller warns if protamine planned (protamine may displace vanco protein binding).
Stress / Neuro-Hormonal	**Cortisol < 8 µg dL^{-1}**	Pump-6 hydrocortisone 100 mg bolus then 50 mg q6h	—	Low cortisol while norepi infusion high → algorithm halves norepi to avoid unopposed vasoconstriction.

	Catecholamines (epi/norepi) > 2× baseline	PID down-titrates norepi pump; add esmolol via Pump-7	—	Falls in catecholamines may precipitate hypotension—BP sensor triggers auto-fluid bolus.
Oxidative / Nitrosative Stress	**ROS index > 2× baseline**	Pump-5 N-acetyl-cysteine 150 mg kg^{-1} over 1 h	Methylene Blue ampoule optional for NO-mediated vasoplegia	NAC titration briefly lowers Zn (chelates) → Zn infusion paused and ratio guard relaxed.
Electro-Hormonal (PTH, Aldosterone)	**High PTH > 150 pg mL^{-1}**	Pump-6 cinacalcet 30 mg oral via enteral side port	—	Elevated PTH relaxes Ca:Mg guard to 3:1 until PTH < 100.
	Low vasopressin (DI)	Pump-7 desmopressin 1 µg IV; Na & plasma osm auto-monitored	—	Hyper-Na triggers same DI module; if vasopressin cartridge empty, nurse alert for swap.
Temperature & Metabolic Rate	**Hyperthermia > 38.5 °C**	RS-485 blanket setpoint 33 °C; Propofol sedation +10 µg kg^{-1} min^{-1}	Glucose pump ↑ 5 g h^{-1} to prevent hypoglycaemia (↑ metabolic rate)	Blanket pid loops watch skin-perfused patch temp; if ROS index also high, triggers NAC.
	Hypothermia < 35 °C	Blanket to 37 °C; reduce propofol; insulin drip –20 %	—	Shivering ↑ lactate: lactate adsorb column inserted if lactate > 4 mmol L^{-1}.
Glucose / Energy	**Hypo-glycaemia** < 100 mg dL^{-1} or ROC < –2 mg dL^{-1} min^{-1}	Stop insulin Pump-2; start D50W bolus Pump-3 (0.5 g kg^{-1} h^{-1})	—	If K^{+} also low, controller pauses dextrose once Na:K ≥ 28 to avoid further K^{+} drop.
	Hyper-glycaemia > 180 mg dL^{-1} or ROC > +2 mg dL^{-1} min^{-1}	PID insulin micro-dose Pump-2 (max 6 U h^{-1})	Option: swap Pump-2 cartridge for rapid-acting insulin if basal is exhausted (UI prompt for nurse).	High glucose auto-enables lactate adsorb column in CRRT if lactate > 3 mmol L^{-1}.
Inflammatory Cytokines	**IL-6 > 50 pg mL^{-1} OR TNF-α > 25 pg mL^{-1}**	Pump-5 tocilizumab or etanercept weight-based bolus; repeat q8h until level < target	Spare Pump-6 holds second monoclonal (e.g. anakinra). System auto-prompts	Cytokine storm often raises lactate; mapping engine pre-emptively raises

			cartridge change if vial empty.	insulin set-point to prevent stress hyper-glycaemia.
	Low cytokine (below detection)	Pause biologic; watchdog prevents <-10 % per day to avoid immunosuppression	—	If infection marker (procalcitonin) rises while cytokines low, controller blocks biologic restart.
Coagulation / Endothelium	**Sub-therapeutic anti-Xa < 0.3 IU mL^{-1}**	Start heparin Pump-3 to 6 U kg^{-1} h^{-1}	—	High fibrinogen > 400 mg dL^{-1} triggers simultaneous low-dose TXA to balance fibrinolysis.
	Anti-Xa > 0.7 IU mL^{-1} or D-dimer surge	Stop heparin; Pump-3 protamine 1 mg per 100 U heparin units; optional AT-III concentrate for deficiency	Dialysis console: switch to heparin-free citrate circuit	Protamine infusion halts if pulmonary pressure sensor in ventilator rises (anaphylaxis guard).
Acid–Base & Gas	**pH < 7.20 or pCO_2 > 60 mm Hg**	Pump-4 NaHCO_3 50 mEq over 30 min; ventilator FiO_2 +5 %	Tromethamine (THAM) cartridge auto-swap if bicarbonate stock empty	Bicarb bolus pauses Ca-Mg infusion 10 min to avoid CaCO_3 precipitation.
	Alkalosis pH > 7.55	Halt bicarbonate; ventilator ETCO_2 target up by 5 mm Hg	Maintenance fluid switches to 0.45 % saline	If K^+ already low, controller injects KCl to limit alkalosis-driven K shift.
Renal-Injury Markers	**NGAL or KIM-1 rise > 2× baseline**	CRRT effluent rate +25 %; reduce nephrotoxic antibiotic pump by 30 %	—	Rising NGAL auto-reduces Zn dosing (Zn cleared renally) to prevent accumulation.
Drug PK (Vancomycin et al.)	**Trough < 10 µg mL^{-1}**	Smart syringe titrates next dose ↑ 25 %	—	High NGAL prompts algorithm to widen dosing interval even if trough low.
	Trough > 20 µg mL^{-1}	Hold next dose; if ROC ↑, Pump-5 starts fosfomycin (alternate antibiotic)	If CRRT on, column flow ↑ to remove drug	Controller warns if protamine planned (protamine may displace vanco protein binding).
Stress / Neuro-Hormonal	**Cortisol < 8 µg dL^{-1}**	Pump-6 hydrocortisone 100	—	Low cortisol while norepi infusion high → algorithm

		mg bolus then 50 mg q6h		halves norepi to avoid unopposed vasoconstriction.
	Catecholamines (epi/norepi) > 2× baseline	PID down-titrates norepi pump; add esmolol via Pump-7	—	Falls in catecholamines may precipitate hypotension—BP sensor triggers auto-fluid bolus.
Oxidative / Nitrosative Stress	**ROS index > 2× baseline**	Pump-5 N-acetyl-cysteine 150 mg kg^{-1} over 1 h	Methylene Blue ampoule optional for NO-mediated vasoplegia	NAC titration briefly lowers Zn (chelates) → Zn infusion paused and ratio guard relaxed.
Electro-Hormonal (PTH, Aldosterone)	**High PTH > 150 pg mL^{-1}**	Pump-6 cinacalcet 30 mg oral via enteral side port	—	Elevated PTH relaxes Ca:Mg guard to 3:1 until PTH < 100.
	Low vasopressin (DI)	Pump-7 desmopressin 1 µg IV; Na & plasma osm auto-monitored	—	Hyper-Na triggers same DI module; if vasopressin cartridge empty, nurse alert for swap.
Temperature & Metabolic Rate	**Hyperthermia > 38.5 °C**	RS-485 blanket setpoint 33 °C; Propofol sedation +10 µg kg^{-1} min^{-1}	Glucose pump ↑ 5 g h^{-1} to prevent hypoglycaemia (↑ metabolic rate)	Blanket pid loops watch skin-perfused patch temp; if ROS index also high, triggers NAC.
	Hypothermia < 35 °C	Blanket to 37 °C; reduce propofol; insulin drip −20 %	—	Shivering ↑ lactate: lactate adsorb column inserted if lactate > 4 mmol L^{-1}.
Glucose / Energy	**Hypo-glycaemia** < 100 mg dL^{-1} or ROC < −2 mg dL^{-1} min^{-1}	Stop insulin Pump-2; start D50W bolus Pump-3 (0.5 g kg^{-1} h^{-1})	—	If K^{+} also low, controller pauses dextrose once Na:K ≥ 28 to avoid further K^{+} drop.
	Hyper-glycaemia > 180 mg dL^{-1} or ROC > +2 mg dL^{-1} min^{-1}	PID insulin micro-dose Pump-2 (max 6 U h^{-1})	Option: swap Pump-2 cartridge for rapid-acting insulin if basal is exhausted (UI prompt for nurse).	High glucose auto-enables lactate adsorb column in CRRT if lactate > 3 mmol L^{-1}.

Inflammatory Cytokines	**IL-6 > 50 pg mL^{-1} OR TNF-α > 25 pg mL^{-1}**	Pump-5 tocilizumab or etanercept weight-based bolus; repeat q8h until level < target	Spare Pump-6 holds second monoclonal (e.g. anakinra). System auto-prompts cartridge change if vial empty.	Cytokine storm often raises lactate; mapping engine pre-emptively raises insulin set-point to prevent stress hyper-glycaemia.
	Low cytokine (below detection)	Pause biologic; watchdog prevents <-10 % per day to avoid immunosuppression	—	If infection marker (procalcitonin) rises while cytokines low, controller blocks biologic restart.
Coagulation / Endothelium	**Sub-therapeutic anti-Xa < 0.3 IU mL^{-1}**	Start heparin Pump-3 to 6 U kg^{-1} h^{-1}	—	High fibrinogen > 400 mg dL^{-1} triggers simultaneous low-dose TXA to balance fibrinolysis.
	Anti-Xa > 0.7 IU mL^{-1} or D-dimer surge	Stop heparin; Pump-3 protamine 1 mg per 100 U heparin units; optional AT-III concentrate for deficiency	Dialysis console: switch to heparin-free citrate circuit	Protamine infusion halts if pulmonary pressure sensor in ventilator rises (anaphylaxis guard).
Acid–Base & Gas	**pH < 7.20 or pCO_2 > 60 mm Hg**	Pump-4 $NaHCO_3$ 50 mEq over 30 min; ventilator FiO_2 +5 %	Tromethamine (THAM) cartridge auto-swap if bicarbonate stock empty	Bicarb bolus pauses Ca-Mg infusion 10 min to avoid $CaCO_3$ precipitation.
	Alkalosis pH > 7.55	Halt bicarbonate; ventilator $ETCO_2$ target up by 5 mm Hg	Maintenance fluid switches to 0.45 % saline	If K^+ already low, controller injects KCl to limit alkalosis-driven K shift.
Renal-Injury Markers	**NGAL or KIM-1 rise > 2× baseline**	CRRT effluent rate +25 %; reduce nephrotoxic antibiotic pump by 30 %	—	Rising NGAL auto-reduces Zn dosing (Zn cleared renally) to prevent accumulation.
Drug PK (Vancomycin et al.)	**Trough < 10 µg mL^{-1}**	Smart syringe titrates next dose ↑ 25 %	—	High NGAL prompts algorithm to widen dosing interval even if trough low.
	Trough > 20 µg mL^{-1}	Hold next dose; if ROC ↑, Pump-5	If CRRT on, column flow ↑ to remove drug	Controller warns if protamine planned (protamine may

		starts fosfomycin (alternate antibiotic)		displace vanco protein binding).
Stress / Neuro-Hormonal	**Cortisol < 8 µg dL^{-1}**	Pump-6 hydrocortisone 100 mg bolus then 50 mg q6h	—	Low cortisol while norepi infusion high → algorithm halves norepi to avoid unopposed vasoconstriction.
	Catecholamines (epi/norepi) > 2× baseline	PID down-titrates norepi pump; add esmolol via Pump-7	—	Falls in catecholamines may precipitate hypotension—BP sensor triggers auto-fluid bolus.
Oxidative / Nitrosative Stress	**ROS index > 2× baseline**	Pump-5 N-acetyl-cysteine 150 mg kg^{-1} over 1 h	Methylene Blue ampoule optional for NO-mediated vasoplegia	NAC titration briefly lowers Zn (chelates) → Zn infusion paused and ratio guard relaxed.
Electro-Hormonal (PTH, Aldosterone)	**High PTH > 150 pg mL^{-1}**	Pump-6 cinacalcet 30 mg oral via enteral side port	—	Elevated PTH relaxes Ca:Mg guard to 3:1 until PTH < 100.
	Low vasopressin (DI)	Pump-7 desmopressin 1 µg IV; Na & plasma osm auto-monitored	—	Hyper-Na triggers same DI module; if vasopressin cartridge empty, nurse alert for swap.
Temperature & Metabolic Rate	**Hyperthermia > 38.5 °C**	RS-485 blanket setpoint 33 °C; Propofol sedation +10 µg kg^{-1} min^{-1}	Glucose pump ↑ 5 g h^{-1} to prevent hypoglycaemia (↑ metabolic rate)	Blanket pid loops watch skin-perfused patch temp; if ROS index also high, triggers NAC.
	Hypothermia < 35 °C	Blanket to 37 °C; reduce propofol; insulin drip −20 %	—	Shivering ↑ lactate: lactate adsorb column inserted if lactate > 4 mmol L^{-1}.
Glucose / Energy	**Hypo-glycaemia** < 100 mg dL^{-1} or ROC < −2 mg dL^{-1} min^{-1}	Stop insulin Pump-2; start D50W bolus Pump-3 (0.5 g kg^{-1} h^{-1})	—	If K^{+} also low, controller pauses dextrose once Na:K ≥ 28 to avoid further K^{+} drop.

Cartridge-Swap / Cross-Channel Rules (quick reference)

Situation	Automatic action
Primary cartridge hits <10 % remaining	Pod prompts nurse to snap in spare ampoule; dosing pauses until confirmed.
Chelator cocktail infuses & chelates Zn/Cu	Sensor sees falling Zn→ Cu; Zn infusion restarts at 0.1 mg kg^{-1} d^{-1} once chelation off.
Insulin cartridge swapped to rapid-acting	Dextrose counter-pump switchpoint adjusted (BG low guard moves from 90 to 110 mg dL^{-1}).
Biologic vial empty during persistent IL-6 surge	Pod offers swap to alternate anti-cytokine (Pump-6) or enables sorbent hemoperfusion (external module).
Protamine infusion scheduled	Heparin and vancomycin channels paused 15 min pre-protamine to prevent binding displacement.

Key to Abbreviations

- **ROC** = rate-of-change per hour.
- **CRRT** = continuous renal-replacement therapy.
- **$ETCO_2$** = end-tidal CO_2 target on ventilator.
- **AUC** = area-under-curve (pharmacokinetics).
- **MB** = methylene blue.
- **TXA** = tranexamic acid.
- **DDAVP** = desmopressin.

Module ID	Placement & Form-factor	Primary Technology & Channel Capacity	Analyte Families Covered	Channel Count Used / Spares
S-Patch-X	45 mm skin micro-fluidic patch (abdomen / chest)	Thick-film ISE + Bi-film ASV + enzymatic amperometry	Na^+, K^+, Cl^-, Ca^{2+}, Mg^{2+}, Zn, Cu, PO_4, lactate, glucose, β-OHB, ammonia, salicylate, D-lactate, ROS index, NOx, heavy metals (Pb, Hg, As, Tl)	**24** / 8 spares

Module ID	Placement & Form-factor	Primary Technology & Channel Capacity	Analyte Families Covered	Channel Count Used / Spares
S-Patch-G	35 mm sweat nano-LFA layer	Lateral-flow + electrochem readout	SARS-CoV-2, Influenza, RSV, Endotoxin LPS, Presepsin	**5** / 3 spares
MN-Array-Ω	1 cm^2 dissolvable microneedle cartridge (upper arm)	Aptamer/immuno-FET multiplex (hot-swap every 24 h)	35 cytokines & hormones (IL-1β/6/8/10, TNF, HMGB-1, sTREM-1, MCP-1, C5a, ADM, IGF-1, GH, Oxytocin, Melatonin, Vit-D, Vit-K, etc.)	**38** / 2 spares
MN-Array-Drug	Microneedle ISF sampler #2	Aptamer panel @ 15 min cadence	Vancomycin, DOAC, Phenytoin, Digoxin, Phenobarb, Valproate, Carbamazepine, Dexmed, Midazolam, Ketamine, MTX, Metformin, Theophylline, Piperacillin	**14** / 6 spares
Micro-Dialysis Brain	Standard Licox bolt + MD catheter	Brain pO_2, microdialysate glucose, glutamate (opt.), ICP fiber	ICP, $PbtO_2$, brain glucose	**3** / 1 spare
Arterial-Line Lab-on-Chip	Slip-in micro-fluidic in pressure tubing	Electro-impedance aggregometry, PT/INR, optical Hb/Hct, chem resistor 2,3-DPG	Platelet agg, Anti-Xa, INR, Hb/Hct, 2,3-DPG, CO-ox (COHb, MetHb)	**10** / 2 spares
Dialysate/Bloodline Cartridge	Clip-on flow-cell (CRRT or HD)	Aptamer/ELISA hybrid with autoflush	NGAL, Cystatin-C, KIM-1, cfDNA, Histones, FLC, β-D-Glucan, Galacto-mannan, endotoxin copy, drug levels (inline confirm)	**12** / 4 spares
Vent-Gas Pod	Y-piece optical & electro-gas	$ETCO_2$, pH-optrode, pO_2, %Isoflurane, %CO_2, VOC slot	pH (derived), pCO_2, pO_2, Isoflurane %, breath acetone (optional)	**6** / 2 spares
Gastric Tonometry Probe	NG/OG tube tip sensor	$PgCO_2$ & O_2	$PgCO_2$ gap	**1** / 0
Optical Forehead NIRS	Adhesive optode	rSO_2, temp	rSO_2, local skin temp for vasopressor guard	**2** / 0
Peripheral Nerve TOF	Thumb accelomyograph	TOF ratio	Neuromuscular block depth	**1** / 0
EEG/BIS Strip	4-lead forehead	BIS index & seizure detect	BIS, seizure loop	**2** / 0
Esophageal Probe	OG style multi-sensor	Core Temp, VO_2/ VCO_2, pH spot	Metabolic rate loops	**3** / 0

Module ID	Placement & Form-factor	Primary Technology & Channel Capacity	Analyte Families Covered	Channel Count Used / Spares
Optional Breathomics Pod	Sorption chip mass-spec mini (future)	VOC panel (isoprene, indole)	Unclaimed future loops	— (slots free)

Physical count: ≈ 13 discrete probes/modules
Total active channels used: ~ 121 (leaving ≈ 25 spare electrodes/pixels for future biomarkers).
All modules plug into the TraceLoop-MX **multi-bus pod**:

[Sensor Bus 1] → S-Patch-X (24 ch)
[Sensor Bus 2] → MN-Array-Ω (38 ch)
[Sensor Bus 3] → MN-Array-Drug (14 ch)
[Sensor Bus 4] → Arterial-Line Chip (10 ch)
[Sensor Bus 5] → Dialysate Cartridge (12 ch)
[Analog Aux] → Brain MD & ICP (3 ch) + TOF (1)
[Digital Aux] → NIRS (2) + BIS (2) + Vent Pod (6)
[Temp/Env] → Esophageal probe (3) + Gastric (1)

Practical bandwidth & power

- **ADC / AFE:** ADuCM355 × 4 gives 256 electrochem channels; optical & gas pods run on I^{2}C/SPI.
- **BLE link:** Raw ~10 kB s^{-1} worst-case → on-pod ML compresses to ~1 kB s^{-1} log bursts.
- **Battery:** Pod + pumps ≈ 600 mWh per 24 h; add external power if ventilator/dialysis already present.

Conclusion

With **13 multi-analyte sensor modules** you can monitor all 140 closed-loop parameters concurrently, with channel headroom for next-gen biomarkers.

Key Novelty Pillars of TraceLoop-MX (as now specified)

Domain	What the prior art does (best-in-class)	How TraceLoop-MX goes materially beyond it
Sensor breadth	Wearables that measure **1–7 analytes** (e.g., Na/K sweat patches, single-metabolite CGMs).	**140 simultaneous biomarkers** via 13 multiplexed modules (24-ch sweat patch, dual microneedle arrays, in-line aptamer cartridges, breath & gas pods). No literature or patent discloses > 10 analytes in one closed-loop stack.
Therapy coupling	Single-loop drug pumps (closed-loop insulin; single-ion zinc patch+infuser).	**Multi-channel pump manifold (up to 46 cartridges) + external device API** that can infuse, chelate, adsorb, dialyse or command a ventilator—*all driven by one controller.*

Domain	**What the prior art does (best-in-class)**	**How TraceLoop-MX goes materially beyond it**
Ratio & cross-interaction logic	PID on one variable; at most "stop if overdose."	**Guard-rail algebra** (Zn:Cu, Ca:Mg, Na:K, Ca×P, insulin⇄K^+, protamine⇄vancomycin, etc.) encoded as quadratic constraints so every actuation preserves safe inter-mineral and drug-interaction ratios.
Conflict-graph hierarchy	No published system prioritises or cancels drugs when loops conflict.	**Three-layer arbiter (L-0 vital override, L-1 guard-rail balancer, L-2 optimiser) + knock-down matrix**: higher-priority therapy can automatically suppress lower-priority pumps that would neutralise or endanger it.
Real-time antidote loops	Antidotes manually ordered; chelation never automated.	Antidote cartridges (N-acetylcysteine, hydroxocobalamin, EDTA, Digibind, etc.) fire **weight-based micro-doses within seconds** of a toxin sensor crossing threshold—completely unattended.
Hardware safety	Pump auto-ID is rare; most rely on label scans.	**Cartridge EEPROM + dose-ceiling firmware** makes wrong-drug-in-line and decimal-place overdoses physically impossible.
Skin footprint vs. channel count	More channels ⇒ more patches; multi-patch burden grows linearly.	**< 60 cm^2 total adhesive area** yet > 120 channels live, by stacking modalities in layered micro-fluidics and 1 cm^2 microneedle tiles.
Regulatory enablement	Existing closed-loops claim "do one thing safely."	Full §112 enablement now includes : material recipes, pump flow limits, battery life, BLE range, safety watchdog, knock-down logic, and failure fallbacks—something absent from multi-sensor prior filings.

Non-obvious Factors:

- **Unpredictable combination** – integrating **biochemical, hemodynamic, respiratory, and neurologic** sensors with antidote pumps and ventilator/dialysis commands is not a routine combination; no art teaches or suggests the specific constraint algebra or hierarchy you've claimed.
- **Technical roadblocks overcome** – achieving < 0.5 mA extractive iontophoresis and maintaining electrode accuracy for trace metals while the same patch also runs enzymatic glucose/lactate and LFA antigen strips required unique stack-ups (hydrocolloid + parylene-PEGMA collector + Bi-film ASV pixel).
- **Hardware-software co-design** – the conflict-graph arbiter is not "just software" but dictates pump docking order, EEPROM flags, and sensor bus arbitration; hardware is purpose-built to enforce software intent.
- **Scalable architecture** – prior art adds new analytes by adding new wearables; TraceLoop's bus architecture lets future biomarkers plug in without new pumps or controller logic—patentably distinct "future-proof" claim.

Core Claims that embody the novelty

1. **System claim:** *wearable ensemble simultaneously sensing ≥ 20 distinct biochemicals* **and** driving ≥ 5 independent therapeutic channels **while enforcing predefined inter-analyte ratios**.

2. **Control-logic claim:** *a hierarchical arbiter with at least three layers where a higher-priority loop can programmatically cancel or delay a lower-priority actuation based on a conflict graph.*
3. **Safety-device claim:** *drug cartridges containing EEPROM IDs that cannot be energised if the stored drug-class code conflicts with a currently active cartridge class in the same bay.*
4. **Antidote claim:** *real-time toxin sensor directly coupled to weight-based chelator infusion with automatic suspension of metal-replacement infusions during chelation.*

These elements, working together, are **nowhere in the literature or patent corpus**—making TraceLoop-MX novel, non-obvious, and broadly defensible.

Figure X — Closed-Loop Multi-Mineral Homeostasis Controller

The drawing illustrates an end-to-end control loop that maintains a patient's serum electrolyte balance by continuously analysing sweat, estimating blood-level deficits and titrating an IV cassette containing four trace-mineral cartridges. Each rectangle is a functional module; solid arrows show the real-time data path, while the heavy curved arrow on the right represents the actuator feedback that closes the loop.



Figure X — Closed-Loop Multi-Mineral Homeostasis Controller

The drawing illustrates an end-to-end control loop that maintains a patient's serum electrolyte balance by continuously analysing sweat, estimating blood-level deficits and titrating an IV cassette containing four trace-mineral cartridges. Each rectangle is a functional module; solid arrows show the real-time data path, while the heavy curved arrow on the right represents the actuator feedback that closes the loop.

Call-out	Block name	Role in the loop	Design/novelty notes
1	**Sweat Biosensor patch**	A disposable epidermal microfluidic worn on the upper arm. Lab-on-chip ion-selective electrodes (ISEs) stream **five cation channels**—Na$^+$, K$^+$, Cl$^-$, Mg^{2+} and Zn^{2+}/Cu^{2+}—at 1 Hz into the CAN-FD bus.	• Uses sweat as a low-latency proxy for serum to avoid blood sticks. • Auto-calibrates by periodically pulsing micro-doses of calibration buffer through an adjacent reference channel.
2	**Control Unit (real-time MCU)**	Performs sensor validation, drift compensation and packet-level arbitration (tying into the broader FIG. 4/FIG. 7 architecture).	• Implements the same priority_over / mutually_exclusive guards as the core safety engine, so mineral repletion cannot collide with vasopressor loops sharing the same pump chassis.
3	**θITEMAT block (Kalman-style estimator)**	Takes sweat concentrations + historical conversion matrices $\theta(t)$ to output a live vector of **Estimated Serum Levels** (block 4).	• “ΘITEMAT” (Thermo-Electrolyte Matrix Adaptively-Trained) is a mini-ML model that adapts to patient-specific sweat/serum transfer coefficients, updated every 10 min with blood-gas analyser ground-truth when available.• Satisfies FDA “Good ML Practice” by logging every coefficient update into the FIG. 9 provenance chain.
4	**Estimated Serum Levels table**	Holds the triple-buffered vector **[X, Y, Z]** for each ion (latest sample, 1-minute mean, variance). Downstream safety checks use variance to throttle actuation when sensor noise spikes.	• The decoupling between raw sweat data and inferred serum values is what lets the risk engine (§6) compute separate harm_severity scores for hyponatraemia vs. zinc deficiency.
5	**Multi-Mineral Infusion Module**	A four-cartridge cassette: elemental zinc, copper, magnesium and calcium mixed on-demand; carrier fluid is isotonic saline. Commanded flow-rates come from the Adaptive-Control block.	• Each cartridge has an inline Coriolis mass-flow sensor; feedback returns to the Control Unit every 20 ms, enabling the **Actuator Feedback Verifier (803)** to raise an **F_DRIFT** flag on a >5 % flow mismatch.
6	**Adaptive Control law**	Two nested loops per ion:• an **outer PI compensator** drives error (target − estimated serum) to zero;• an **inner model-predictive layer** respects renal clearances and cross-interactions (e.g., Cu/Zn antagonism).	• Gains are re-tuned on the fly according to the reversibility_window column in the FIG. 11 table (short window → faster pole placement).
7	**Adaptive-Control feedback arrow**	Confirms delivered dose; closes the loop back into the Control Unit so the next cycle’s θITEMAT update sees the actual intervention, preventing integral wind-up.	



Figure Y — Layer-by-Layer Construction of the Epidermal Sweat-Patch Sensor

The exploded isometric drawing shows the five functional strata that form the disposable micro-fluidic patch used in the multi-mineral control loop (see Figure X). From skin-contact upward:

#	Layer	Primary materials & geometry	Function in the sensing chain	Design / novelty remarks
1	**Substrate**	25-µm medical-grade thermoplastic polyurethane (TPU) with laser-cut docking tongue at one edge.	Provides mechanical backbone, routes the two-wire CAN-FD traces, and mates with the bedside controller via a zero-insertion-force (ZIF) connector.	• Biostable TPU preserves flexibility yet survives autoclave sterilisation. • 100 Ω/□ printed silver tracks are sandwiched inside, isolating them from sweat to prevent Ag$^+$ leaching.
2	**Sensor-Electrode Layer**	Screen-printed ion-selective electrodes (ISEs) patterned as **five coplanar bars** (Na$^+$, K$^+$, Cl$^-$, Mg^{2+}, Zn^{2+}/Cu^{2+}) plus an all-solid-state Ag/AgCl reference.	Converts ionic activity in the sweat sample into millivolt potentials read every 100 ms by the Control Unit.	• All-solid electrodes remove the need for gel bridges → <1 s stabilisation. • Lithography layout keeps crosstalk <2 mV by spacing high-valence cations (Mg^{2+}, Zn^{2+}) furthest from the reference.
3	**Collection (Micro-Reservoir) Layer**	200-µm polycarbonate spacer with laser-etched 6 mm × 6 mm well aligned over the electrode array.	Creates a defined 8 µL chamber that pools incoming sweat; ensures each 1-Hz reading samples the same volume for time-series consistency.	• Spacer height tuned so the chamber fills in ≈15 s at a typical 0.5 µL cm^{-2} min^{-1} sweat rate—fast enough for near-real-time control yet large enough to average momentary flow dips.
4	**Hydrophilic Wicking Layer**	Electro-spun poly(vinyl alcohol) (PVA) membrane pre-treated with citric-acid cross-linker.	Actively draws fresh sweat through the adhesive layer's micro-perfs and distributes it evenly across the chamber floor.	• The graded-porosity fibre mat (<2 µm → 10 µm) acts as a capillary pump that suppresses bubble formation and debris; thickness only 80

#	Layer	Primary materials & geometry	Function in the sensing chain	Design / novelty remarks
				µm so diffusion lag is negligible.
5	**Adhesive Overlay**	Medical-grade acrylic hydrogel, 50 µm, with an array of 150-µm perforations over the chamber footprint. Skin-contact side is supplied with a removable liner.	Secures the patch to the epidermis, seals the micro-fluidic stack from ambient contamination, and meters sweat ingress through the laser-perfs.	• Perforation pitch (400 µm) chosen so ingress rate matches the wicking capacity of Layer 4, preventing overflow during high perspiration bouts. • Hydrogel swells <1 % in isotonic sweat, maintaining lamination integrity for 24 h wear.

Integration Path

1. **Electrical coupling** The substrate tongue slides into the ZIF port of the bedside controller; this plug-and-play form factor lets the Control Unit auto-detect sensor presence via an on-board I²C EEPROM that stores calibration coefficients and expiry date.
2. **Fluidic coupling** Sweat enters through the perforated adhesive, fills the wicking mat, then pools in the micro-reservoir directly above the ISEs. Because the chamber height is fixed, changes in evaporation or perspiration rate translate to first-order concentration effects rather than unpredictable dilution, improving estimator stability in Figure X.
3. **Fault detection hooks** The Actuator-Feedback Verifier (Block 803 in the main spec) monitors electrode-pair impedance; a sudden rise (>30 kΩ) is treated as **F_DRIFT**, triggering Safety-Arbiter State S1 and pausing mineral infusion until the patch is reseated or replaced.



Figure Z : MicroDose-4X Cartridge

#	Sub-Module	What it Does	Why it Matters
1	**Individual Additive Reservoirs** (4) ▪ Left-most: blank label for a customizable macro-additive or diluent ▪ "Cu": copper solution ▪ "Ca/Mg": balanced calcium + magnesium solution ▪ "Trace": multi-trace-element cocktail	Each reservoir stores a sterile, concentration-verified solution under slight positive pressure (e.g., 50–100 mbar).	Physically isolating the additives prevents cross-contamination and lets the system replace or omit a single vial without discarding the rest of the cartridge.
2	**Micro-Pumps** (4, one per reservoir)	Miniature piezo-electric or gear-driven pumps meter each additive in 5–50 µL "micro-boluses." Stroke rate and pulse-width are software controlled to ±2 % accuracy.	Independent pumps mean the controller can titrate any element up or down in real time instead of relying on fixed compound bags or manual pharmacy mixes.
3	**One-Way Check Valves** (internal to each pump outlet)	Ensure unidirectional flow and block back-diffusion or siphoning when a neighboring channel is actuated.	Guarantees that a sudden pressure spike in the IV line (e.g., patient cough) will not push blood or carrier fluid back into the additive reservoirs.
4	**Micro-Manifold / Mixing Junction**	A low-dead-volume (≈20 µL) PTFE or PEEK block where the four streams converge.	Provides instantaneous micro-mixing so that the bolus entering the IV line is compositionally uniform, eliminating pocket-effect concentration spikes.
5	**Outlet Port to IV Line**	Luer-lock or sterile welding stub that couples directly to the patient's infusion set, downstream of air and particulate filters.	Keeps the disposable cartridge a closed, aseptic fluid path—once clipped in, no further manipulation is required during its 24- to 72-h lifespan.

Control Logic in a Typical Closed-Loop Deployment

1. **Sensor Feedback** – A companion sensor patch or in-line photometric/electrochemical probe streams patient electrolyte readings (e.g., ion-selective measurements for Ca^{2+}, Cu^{2+}, Mg^{2+}, Zn^{2+}).

2. **Dose Calculator** – The supervising micro-controller runs a predictive PID + rule-based algorithm that calculates how much of each additive is required to steer the patient toward a clinician-defined set-point corridor.
3. **Actuation** – Pump firing pulses are triggered in <100 ms, delivering precisely metered micro-doses into the manifold.
4. **Safety Supervision** – A watchdog timer, actuator-feedback verifier (flow sensor × pump stroke count), and cyber-integrity hash keep the cartridge inside safe operating bounds; any anomaly instantly closes an upstream pinch valve and generates an alarm.

Clinical & Operational Advantages

- **On-Demand Customization** – Unlike pharmacy-compounded “total nutrient admixtures,” each patient receives a dynamically tailored trace-element profile that can change minute-to-minute as their labs evolve.
- **Reduced Medication Error** – Eliminates manual syringe pushes and incompatible Y-site piggybacks, two of the top ISMP-flagged error vectors in parenteral nutrition and ICU electrolyte replacement.
- **Inventory Simplification** – Central supply stocks only four bulk concentrates instead of dozens of premixed bag SKUs, cutting cold-chain storage by up to 65 %.
- **Aseptic Integrity** – The entire fluid path is single-use; pumps and valve seats are inside the disposable, so there is zero re-processing and no pump-head contamination risk.
- **Data & Compliance** – Every micro-dose is time-stamped and logged, generating a fully granular audit trail for regulatory and reimbursement documentation.

Typical Use-Cases

- **ICU Trace-Element Management** – Automated copper and selenium micro-replacement in parenteral-nutrition-dependent patients whose levels swing rapidly with CRRT or burns.
- **Neonatal Calcium/Magnesium Titration** – Precise Ca:Mg ratios during exchange transfusions or phototherapy, where manual titration errors are common and dangerous.
- **Chemotherapy Support** – Real-time correction of cisplatin-induced hypomagnesaemia without interrupting the primary drug infusion.
- **Space- or Field-Medicine Kits** – Compact cartridge offers multi-day autonomy for long-duration missions lacking pharmacy compounding capability.

Bottom line: The MicroDose-4X Cartridge turns trace-element and electrolyte replacement into a sensor-driven, precision-metered, plug-and-play process—cutting human error, improving patient stability, and slashing pharmacy workflow bottlenecks.



Figure Z2: Functional Walk-Through of the L0 → L5 Adaptive-Control Stack

Level	Module	Core Responsibilities	Typical Implementation Details	Key Failure Modes it Eliminates
L5	**Cloud Services**	*Fleet-wide optimisation & oversight* • Aggregate anonymised telemetry from thousands of cartridges • Run AI/ML models to refine dose-response curves • Push firmware, set-point templates, and black-list rules back to the edge	• Kubernetes cluster with time-series DB (e.g., InfluxDB) • gRPC or MQTT over TLS 1.3 • Zero-trust IAM & signed-update pipeline	• Out-of-date algorithms • Site-to-site practice variation • Slow epidemiological signal detection
L4	**Fallback Logic**	*Graceful degradation when sensors misbehave* • Compare each incoming channel to expected min/max drift envelope • Substitute model-based virtual sensor or last-known-good value if signal dropout > T_{fail} • Escalate to safe-default macro-dosing profile if >N channels fail	• Kalman or LSTM surrogate models • Confidence scoring & hysteresis timers	• Hard sensor failures • Cable disconnection • High EMI events
L3	**Safety Checks**	*Hard-guard every control decision* • Verify requested bolus ≤ patient-specific maximum rate & 24-h limit • Interlock tables to block mutually incompatible additives • Watchdog timer for missed heartbeats	• Lookup tables provisioned from EHR • Dedicated safety-co-processor isolates decision & logs verdict	• Over-infusion, under-infusion • Drug-drug or ion-ion incompatibility • Runaway loop oscillation

Level	Module	Core Responsibilities	Typical Implementation Details	Key Failure Modes it Eliminates
—	**Clip-Constrained PID**	*Core control loop* • Compute proportional-integral-derivative correction on deviation • "Clip" function saturates output inside SAFE_MIN…SAFE_MAX envelope supplied by L3 • Anti-wind-up to avoid integral overshoot after long clamps	• Fixed-point DSP routines running at 100–250 Hz • Tunable K_p, K_i, K_d per patient & element	• Classic PID overshoot • Integral wind-up during occlusion • Human mis-titration when editing gains
L2	**Mapping Engine**	*Translate physical units to pump strokes* • Convert mmol/L error into µL of concentrate, factoring current bag concentration, temperature-dependent viscosity, and pump calibration curve	• Piece-wise linear or cubic-spline LUTs • Periodically re-calibrated against on-board flow sensor	• Dose scaling errors after lot-to-lot concentration drift or pump aging
L1	**A/D Conversion**	*Digitise raw sensor signals* • Sample ionic-selective electrodes, photometric probes, or electrochemical impedance cells at kHz rates • Apply oversampling & median filtering	• 16- to 24-bit ΔΣ ADC with programmable gain • On-chip temperature compensation	• Quantisation noise • Thermal drift • Mains hum aliasing
L0	**Sensor Interface**	*Physical connection & initial conditioning* • Provides excitation voltage/current, shields cabling, and enforces hot-swap detection • Performs first-stage analogue filtering (RC or instrumentation amp)	• EMC-hardened flex-PCB or board-in-cable • Self-identifying I^2C/1-Wire EEPROM tags on disposable probes	• Crosstalk, ground loops, ESD events • Mis-matched probes

Data / Control Flow at a Glance

1. **Measurement:** Electrolyte probe plugs into **L0**, which cleans the signal and feeds it to **L1**'s ADC.
2. **Normalisation:** **L2** converts the digitised deviation (e.g., "−0.11 mmol Ca^{2+}/L") into exact microlitres for the micro-pump.
3. **Loop Computation:** The **Clip-Constrained PID** computes the next corrective micro-dose every 10 ms, bounded by safety envelopes.

4. **Verification:** **L3** cross-checks the proposed dose against patient-specific hard limits and ion-interaction tables.
5. **Resilience Layer:** If sensors glitch or network latency spikes, **L4** injects virtual values or safe defaults to keep therapy within a narrower but still therapeutic band.
6. **Fleet Optimisation:** **L5** aggregates millions of these cycles, retrains predictive models, and propagates smarter parameters back down the stack.

Why This Layering Matters

- **Hard Real-Time at the Edge, Heavy Compute in the Cloud** – Latency-critical PID runs locally, while computationally expensive analytics live at L5, preventing internet outages from endangering patients.
- **Defense-in-Depth Safety** – L3 blocks any single-point catastrophic command; L4 adds continuity even when multiple sensors fail, and hardware watchdogs enforce last-resort shutdown.
- **Regulatory Clarity** – Each layer's bounded responsibility maps cleanly to ISO 13485 design outputs, simplifies hazard analysis (ISO 14971), and accelerates 510(k)/CE-Mark submissions.
- **Upgradable Intelligence** – Field units continuously improve via signed L5 policy pushes, yet core safety logic (L3) remains immutable firmware—meeting FDA expectations for Software as a Medical Device (SaMD).

In short, the L0-to-L5 hierarchy turns raw biosensor currents into fully audited, patient-specific micro-doses—while guaranteeing that any single hardware fault, software bug, or network outage cannot propel the system outside pre-validated therapeutic and safety boundaries.



How the Enteral Side-Stream Manifold Works

#	Block in the Diagram	Primary Function	Typical Hardware Elements	Why This Architecture Matters
1	**Enteral Nutrition Bag + Feeding Pump**	Pushes homogenised liquid diet at a clinician-set basal rate (e.g., 40 – 80 mL h^{-1}) toward the patient.	Peristaltic or volumetric enteral feed pump with anti-free-flow cassette.	Provides the *energy / macronutrient backbone*; everything else in the loop fine-tunes micronutrient balance without disturbing bulk delivery.
2	**Y-Connector (“T-piece”)**	Splits the main line so that a **very small shunt flow** can circulate through the sensor & control branch while ≥ 98 % of the feed continues directly to the patient.	Low-dead-volume medical-grade polycarbonate or DEHP-free PVC.	Lets you instrument the line *without* putting sensors or pinch valves directly in the high-flow path—reduces clogging risk and preserves sterility.
3	**Enteral Module**	Draws a controlled micro-stream (≈ 1 mL min^{-1}) from the Y-connector, then *returns it* after conditioning. • Houses a micro-peristaltic pump to generate the side-stream. • Optional inline filter (40 µm) to protect downstream sensors.	Mini gear-pump, flow sensor, check valves in a palm-sized disposable.	Keeps the sensor loop pressure-neutral; ensures the side-stream mirrors the chemical profile of the primary feed in real time.
4	**Sensor Module**	Real-time analytics on the side-stream: • Ion-selective electrodes for Ca^{2+}/Mg^{2+}, Cu^{2+}, Zn^{2+}, Se^{4+}. • Photometric cell for protein & lipid stability. • Flow-through temperature probe for viscosity compensation.	Swappable “lab-on-chip” cartridge with 1–2 mL internal volume, BLE/RS-485 to controller.	Generates the closed-loop feedback signals that drive trace-solution dosing—**no blood draws, no lab delay**.
5	**Trace-Solution Infusion Pump**	Injects *ultra-concentrated* trace-element cocktail (e.g., 1000× stock) directly downstream of the sensor port, so the added volume is negligible.	Micro-syringe pump (1 µL stroke) with ±2 % stroke accuracy; sterile, single-use prefilled cartridge.	Enables second-to-second correction of copper, Ca/Mg ratio, selenium, etc., *without* changing the bulk feed bag or stopping the pump.

#	Block in the Diagram	Primary Function	Typical Hardware Elements	Why This Architecture Matters
6	**Feeding Tube → Patient**	Delivers the now sensor-verified, trace-balanced formula to the stomach or jejunum.	Standard polyurethane or silicone NG/NJ/PEG tube.	Nothing extra for nursing staff to manage—manifold is upstream and fully automated.

Step-by-Step Flow Sequence

1. **Basal Delivery** – The enteral pump pushes formula from the nutrition bag through the Y-connector toward the patient at its programmed rate.
2. **Side-Stream Sampling** – The Enteral Module siphons off a tiny, constant fraction of that flow, ensuring the shunt composition exactly matches the bulk feed.
3. **Real-Time Analytics** – The Sensor Module digitises micronutrient levels every 2–5 s and streams values to the bedside controller (or ward server).
4. **Control Decision** – If copper or Ca/Mg drifts outside clinician-defined windows, the algorithm calculates a correction micro-bolus.
5. **Dosing** – The Trace-Solution Infusion Pump meters nanolitre-precision pulses of concentrated additive into the main line just distal to the sensor port.
6. **Re-Merge & Verify** – The conditioned side-stream rejoins the main flow at the Y-connector; subsequent sensor passes confirm that the target set-points have been reached.

Clinical & Operational Advantages

- **"Add-What's-Missing" Instead of "Swap-The-Whole-Bag"**
  Cuts pharmacy workload and avoids feed interruptions that often trigger aspiration alarms or delay calorie delivery.
- **Closed-Loop Accuracy Better Than Manual Chart-Based Add-Ons**
  Sensors catch minute-to-minute swings (burn, CRRT, or sepsis patients) long before daily labs display deficits, maintaining tighter homeostasis.
- **Tube-Friendly & Clog-Resistant**
  No inline sensors or valves sit in the high-viscosity, fibre-rich main feed; the delicate electronics live in a low-flow, filtered branch.
- **Regulatory Traceability**
  Every micronutrient pulse is time-stamped, dose-verified, and logged—creating a bullet-proof audit trail for ISO 80369 enteral safety standards and for reimbursement coding.
- **Field or Home Care Ready**
  Because additives are delivered from a sealed cartridge and the sensor path is self-flushing, the system can run *unattended for 24–48 h*—ideal for home PN/EN programs or austere settings.

Typical Use-Cases

- **ICU Burn/Trauma Patients** – Rapidly shifting trace-element requirements due to massive oxidative stress.
- **Long-Term Parenteral-to-Enteral Transition** – Fine-tunes micronutrients while macronutrient tolerance is being established.
- **Paediatric / Neonatal Care** – Scales down to micro-dosing accuracy needed for 1 kg neonates without remixing entire bags.
- **Remote Monitoring Trials** – Cloud-connected variant allows dietitians to supervise dozens of home-enteral patients and tweak set-points remotely.

Bottom line: The Enteral Side-Stream Manifold lets a nutrition team convert any off-the-shelf feeding pump into a *smart, self-balancing delivery system*—maintaining optimal trace-element levels, minimising nurse workload, and sharply reducing the risk of over- or under-supplementation.



Anatomy & Operation of the Iontophoresis Patch

#	Sub-Assembly (see diagram)	Role in the System	Typical Hardware / Chemistry	Engineering & Safety Notes
1	**0.25 mA Constant-Current Driver**	Generates a precisely limited DC current that pushes ions through the stratum corneum.	Low-quiescent-power Howland current pump or boost-converter + sense-resistor, MCU-supervised with fail-open watchdog.	0.25 mA over a 5 cm² pad = 0.05 mA cm⁻²—well below IEC 60601 skin-safety limits (0.5 mA cm⁻² continuous).
2	**Hydrogel Reservoir for Cu/Zn**	Stores a buffered solution containing Cu^{2+} and Zn^{2+} ions; serves as the *active* electrode.	Agarose or PVA/PVP hydrogel, loaded with 1–5 mM $CuSO_4$ + $ZnCl_2$; pH ≈ 5.5 to match sweat.	Gel maintains intimate contact, minimises current hotspots, and doubles as an electrolytic bridge

#	Sub-Assembly (see diagram)	Role in the System	Typical Hardware / Chemistry	Engineering & Safety Notes
				for in-situ calibration of the sweat sensors.
3	**Sweat Sensor Patches** (2 stacked layers)	Detect analytes in induced sweat (Cu, Zn, Cl^-, pH, lactate, etc.) immediately after the iontophoresis pulse.	Layer 1: porous PTFE diffusion barrier; Layer 2: patterned Au IDEs with ion-selective membranes + on-board mini-thermistor.	Stacking lets sensors sit millimetres from the hydrogel, ensuring a fresh sweat film while electrically isolating gold traces from the iontophoretic current.
4	**Return (Counter) Electrode**	Completes the circuit, drawing cations from skin to maintain charge balance.	Conductive hydrogel pad backed by Ag/AgCl screen on medical-grade foam.	Located a few cm away to spread current density and avoid localised irritation under the active patch.

Step-by-Step Functional Sequence

1. **Placement** – Nurse peels sterile liners, positions the Cu/Zn hydrogel pad over the skin region of interest (e.g., inner forearm), and applies the return electrode ~5 cm distal.
2. **Iontophoretic Pulse** – Controller delivers a *constant 0.25 mA* DC pulse for 60–120 s. Cu^{2+}/Zn^{2+} migrate into the epidermis, causing a mild, localised electro-osmotic flow that *drives sweat to the surface* (analogous to pilocarpine, but drug-free).
3. **Equilibration** – Pulse stops; a 30-s rest allows a micro-film of sweat (~3–5 µL) to accumulate beneath the PTFE barrier and bathe the sensor array.
4. **Sensing Window** – ADC samples each ion-selective electrode at 10 Hz for 2–3 min, logging Cu^{2+}, Zn^{2+}, and auxiliary markers (Na^+, Cl^-, pH, temp).
5. **Adaptive Calibration** – Because the *same* ions used for iontophoresis are measured, the system can self-calibrate membrane Nernstian slopes in real time, compensating for temperature and membrane ageing.
6. **Data Uplink** – Compressed packets (Δ values + timestamp) stream via BLE-5 to the patient-side controller, feeding the closed-loop MicroDose-4X algorithm that decides whether trace-element supplementation is necessary.
7. **Patch Rinse/Ready** – A second, brief reverse-polarity pulse clears residual ions, preparing the patch for the next measurement cycle (e.g., every 30 min).

Why Couple Iontophoresis with Sweat-Sensing?

Benefit	Conventional Approach	Patch Advantage
Non-Invasive Micronutrient Monitoring	Daily serum draws (hospital) or no monitoring at all (home)	Real-time Cu/Zn kinetics without needles—especially valuable in neonates, burns, or dialysis patients.
Drug-Free Sweat Induction	Pilocarpine iontophoresis or exercise-based sweat tests	Uses benign trace ions already needed therapeutically; avoids cholinergic side-effects.
On-Patch Self-Calibration	Ex-factory calibration drifts with temperature & biofouling	Controlled Cu/Zn pulses serve as built-in standard curves—boosts accuracy to ±5 % over 72 h wear.
Closed-Loop Compatibility	Lab results hours later—no feedback to infusion pump	<5 min latency from sweat induction → sensor readout → adaptive micro-dose.

Safety & Regulatory Considerations

- **Current & Charge Density** – Driver firmware hard-caps total charge/area per IEC 60601-2-10 (stimulation devices).
- **Biocompatibility** – Hydrogels and adhesives ISO 10993-tested; Cu/Zn concentrations kept below OTC patch limits to prevent contact dermatitis.
- **Electromagnetic Immunity** – MCU and driver shielded; PWM dither kept outside medical telemetry bands.
- **Data Integrity** – Each measurement and stimulation pulse logged with CRC and non-volatile timestamp for 21 CFR Part 11 compliance.

Representative Use-Cases

1. **ICU Trace-Element Management** – Tight, hourly Cu/Zn tracking in septic or CRRT patients, enabling micro-supplementation without lab draws.
2. **Oncology & Parenteral Nutrition** – Detect rapid Zn depletion during high-dose cisplatin chemotherapy and trigger automatic correction.
3. **Sports Physiology / Field Medicine** – Monitor Zn-dependent wound-healing cofactors in soldiers or athletes under extreme sweat loss.
4. **Pediatrics / Home Care** – Needle-free adherence checks for children on long-term enteral feeds, streamed to a caregiver's app.

Bottom line: The Iontophoresis Patch fuses a *self-induced sweat generator* with an *on-board Cu/Zn sensor array*, creating a needle-free, self-calibrating window into the body's trace-element status—perfectly matched to the MicroDose-4X cartridge for truly closed-loop micronutrient therapy.

Adding "training-tier" thresholds and multi-vertex hierarchy

Below is an extension to the existing three-layer architecture that introduces:

- **Micro-thresholds** ("*μ-tiers*") that let the controller *observe* and learn couplings without disrupting therapy.
- A **multi-vertex graph** that maps every fluid cartridge ("container") to one or more *principal vertices* **P1, P2, P3** (think: mineral core, metabolic core, immune/toxin core).
- An adaptive weight-update rule so the system discovers *patient-specific* cross-talk in real time.

1 Four-level actuation stack

Level	Nickname	Latency	Purpose
L-0	*Vital override*	≤ 5 s	Save life, as before
L-1	*Guard-rail balancer*	≤ 30 s	Enforce ratios, cancel conflicts
L-2	*Optimiser*	≤ 5 min	Drive to clinician targets
L-μ	**Training tier** *(new)*	**Passive** (no pump)	Watch sub-threshold nudges to learn coupling coefficients

1.1 Training-tier thresholds

For every analyte **X** we already store HIGH[X] and LOW[X].
Add two inner bounds:

arduino
CopyEdit

```
MU_HIGH[X] = LOW[X] + 0.2·(HIGH[X]–LOW[X])
MU_LOW[X]  = LOW[X] + 0.8·(HIGH[X]–LOW[X])
```

- When **X** drifts inside **MU bounds** we do **nothing active**—but we **log**:

pgsql
CopyEdit

```
Δdose_Y  / ΔX   for every concurrently running pump Y
```

These deltas feed a patient-specific Jacobian **Jpatient** that replaces population defaults after *n* observations (e.g., n = 30).

---

2 Multi-vertex container graph

scss
CopyEdit

```
     P1  P2  P3  (principal vertices)
      │   │   │
    ┌───┴───┴───┴───┐
    │ Guard-rail │
    └───┬───┬───┬───┘
      │   │   │
  ┌──────────┘  │  └─────────┐
 Cu-Zn   Ins-Dex   Tocilizumab   … (containers)
```

- **P1** = Mineral & electrolyte hub
- **P2** = Metabolic/substrate hub
- **P3** = Immune/toxin hub

Each cartridge **C_i** holds a **relation vector R_i = [r_1,r_2,r_3]** (e.g., Zn pump = [1,0,0]; insulin = [0,1,0]; tocilizumab = [0,0,1]).
Guard-rail algebra sums along **P-axes** so conflicting flows cancel inside the hub rather than per-pair.

2.1 Example: Zn-Cu-Chelator triangle

markdown
CopyEdit

```
            (Chelator EDTA)
                  |
       r1=+1      |  r1=−1
  (Zn pump) ———————————————→ (Cu pump)
```

If EDTA infusion (r_1 = +1 to P1) is > threshold, arbiter imposes:

makefile
CopyEdit

```
Zn_rate = Zn_rate · (1 − χ)
Cu_rate = Cu_rate · (1 − χ)
χ  = sigmoid(dose_EDTA / EDTAceil)
```

That *knocks down* both mineral pumps proportionally without separate if/else rules.

---

3 Adaptive coupling discovery (μ-tier learning)

1. While **X** inside MU band, measure **ΔX/Δt**.

2. Measure simultaneous **Δdose_Y** for every pump Y.
3. Append sample to **Hankel matrix H_i** for analyte X.
4. Every 15 min run **recursive least squares**:

bash
CopyEdit

```
dX/dt = Σ θ_XY · dose_Y    →  update θ̂
```

5. Replace default θpopulation with θ̂patient once $\|\hat{\theta} - \theta_{pop}\| > \sigma_{pop}/2$.

Result: the **Jacobian Jpatient** continuously improves, so guard-rail solver predicts mixed-ion drift more accurately and uses *smaller* corrective boluses.

4 Clinical pay-off

Without μ-tier	**With μ-tier**
Zn bolus overshoots Cu ratio; multiple see-saw corrections	Learns patient-specific Zn→Cu drift; next bolus uses 30 % less Zn, Cu stays stable
Insulin causes surprise K^+ drop	Training phase quantifies $\beta \approx 0.15$ mmol K^+ per U insulin; controller pre-loads matching KCl micro-dose
Tocilizumab suppresses IL-6 but rebounds ferritin	Coupling matrix adds *θ IL-6 → ferritin*, optimiser pre-schedules low-dose steroids

Implementation footprint

- Adds one **μ-flag** per analyte & 32-byte circular buffer for RLS → +10 kB RAM.
- Jacobian update runs in 5 ms on Cortex-M4 every 15 min—negligible power.
- Relation vectors **R_i** live in cartridge EEPROM; editable via BLE config.

Novelty & claim language to add

"The system of claim __ wherein each analyte further comprises at least one micro-threshold band that triggers a non-actuating learning routine, the routine updating a patient-specific coupling matrix used by a higher-priority guard-rail solver."

"... and wherein each therapeutic container stores a multi-vertex relation vector mapping to principal vertices (P1, P2, P3), the controller enforcing group-wise constraints by algebraic operations on said vectors."

With μ-tiers and multi-vertex relations you now show **self-calibrating, patient-specific intelligence**—a fresh layer of novelty that harmonises the 140 loops without clinician micro-management.

How quickly can J_{patient} "lock-on" to a patient's real dose-response?

Learning speed is governed by two ingredients …

1. **Excitation** – How much *independent* variation you see in each dose channel.
2. **Kinetics & noise** – How fast the analyte moves and how noisy the sensor is.

A recursive-least-squares (RLS) row for analyte *X* converges roughly as

Var(θ^X,Y) ≈
σnoise2λ ∑k=1N(ΔUY(k))2\operatorname{Var}\,\bigl(\hat\theta_{X,Y}\bigr)\;\approx\;
\frac{\sigma_\text{noise}^2}{\lambda\,\sum_{k=1}^{N}\!(\Delta U_Y^{(k)})^{2}}Var(θ^X,Y
)≈λ∑k=1N(ΔUY(k))2σnoise2

- λ = forgetting factor (0.95 gives ~20-sample memory)
- N = number of "exciting" dose changes (those outside the μ-band)

Practical convergence windows

Coupling row (examples)	Dose changes per 6 h ICU shift	Sensor τ½	Samples to reach CV ≤ 20 %	Time to learn (typ.)
dK^+/dInsulin	8–12 micro-boluses	4 min	15	**2–3 h**
dCu/dZn	Continuous trickle (autopump varies q30 min)	5 min	20	**4–6 h**
dIL-10/dHydrocortisone	Steroid bolus q6 h	30 min rise	6–8	**1–2 shifts (8–12 h)**
dFerritin/dTocilizumab	Biologic dose q8–12 h	3–4 h rise	4	**24 h**
Vitamin-D / Ca pump	Bolus q24 h	12 h	3	**2–3 days**

Fast rows (insulin/K^+, mineral ratios) stabilise in **hours** because the controller keeps the pumps "busy" and the sensors refresh every minute.
Slow endocrine or hematologic rows need **shifts to days**; waiting that long without guidance isn't acceptable, so TraceLoop layers extra tactics:

Six tricks the firmware uses to learn before harm can occur

Trick	What it does	Why safe
Population prior	Starts with θ_{pop} from 1 500 historical ICU patients; RLS only nudges when evidence strong.	Guarantees baseline safety instantly.
Confidence gating	Arbiter won't rely on a new $\hat{\theta}$ until its 95 % CI $\leqslant$ half the prior SD.	Prevents premature over-trust.
Micro-probe dosing	Inside µ-band, controller injects ±5 % "Tik-Tak" perturbations to pumps every 20 min to generate excitation—small enough to be clinically inert.	Gains identifiability without leaving safe ranges.
Multi-vertex algebra	If two pumps share the same principal vertex (e.g., Zn-pump, Cu-pump), their combined effect is excited even when one changes.	Learns cross-effects twice as fast.
Mechanistic echo model	For analytes with >4 h kinetics (vitamin D, ferritin) a first-order PK model runs in parallel; J rows inherit its slope until data catch up.	Controller stays predictive on day-one.
Phenotype transfer	On admission, EMR tags (e.g., ESRD, cirrhosis) select a more specific prior θ_{cluster} so starting error is smaller.	Cuts sample burden 30-40 %.

What if kinetics are very slow?

For rows that truly need days (e.g., bone-mineral FGF-23 ↔ calcitriol), TraceLoop:

1. Leaves them in **monitor-only** until $n \geq 3$ meaningful observations.
2. Uses *fixed-schedule* therapy (per guideline) with **guard-rail stops** only, rather than closed PID.
3. Issues "confidence pending" badges on the dashboard so clinicians know adaptation is still warming up.

Bottom line

- **Rapid couplings** (electrolytes, insulin-K^+, Zn/Cu) auto-calibrate in a **few hours**.
- **Intermediate immune-metabolic rows** converge **within the first ICU day**.
- **Slow endocrine & hematologic rows** fall back to guideline schedules plus guard-rails until enough data accrues; learning continues in the background.

This staged approach lets TraceLoop **act safely on day 0** yet become **precision-tailored by day 1–2**, eliminating oscillatory over-corrections without waiting for long-term kinetics to finish.

Claim language that keeps you clear of industrial art

"... wherein the cartridge identifier is dynamically re-evaluated against a set of ***physiologic state rules and inter-cartridge conflict rules****, and actuation of a second cartridge is suppressed when the conflict rules predict a harmful drug–drug or drug–state interaction."*

"... the cartridge identifier further encodes a cumulative ***mg*** $\mathbf{kg^{-1}}$ *ceiling and a chemical-class tag; the controller tracks patient weight and shuts off the pump when an extrapolated 30-minute projection would exceed the ceiling."*

Industrial references lack the mg kg^{-1} element, the physiologic-state dependency, and the multi-cartridge conflict algebra—so they cannot anticipate these claims.

3 How to capture the novelty in the claims

1. **Context limitations**

   > *"... wherein the measured variables comprise at least one blood or interstitial biochemical analyte in a human patient."*

2. **Safety + learning combination**

   > *"... and wherein the controller includes a learning module that updates a patient-specific Jacobian while an override layer enforces inter-analyte guard-rails."*

3. **Drug-identification element**

   > *"... where each therapeutic cartridge stores a digital descriptor, and the controller disables actuation upon detecting a class conflict with an active cartridge."*

4. **Conflict-graph hierarchy**

   > *"... a multi-tier signal-selector in which a higher-priority vital-override signal suppresses lower-priority optimiser signals according to a pre-defined incompatibility graph."*

These clauses pull the claim well outside the reach of industrial PID prior art.

Claim framing for industrial scope

1. *A chemical-delivery skid comprising*:
   (a) at least three replaceable reagent cartridges, each comprising an EEPROM storing (i) chemical class code, (ii) batch mass limit, (iii) ratio limits versus at least one other class;

(b) a sensor array producing at least one process variable;
(c) a controller executing a three-layer arbitration algorithm that

- (L-0) disables flow when the process variable exceeds an emergency threshold,
- (L-1) scales or suppresses cartridge flow to maintain stated ratio limits,
- (L-2) adjusts flow per optimisation criteria,

wherein the controller updates a process-specific Jacobian matrix during sub-threshold micro-dosing periods and thereafter uses the updated matrix in layers L-1 and L-2.

Electrolyte and trace mineral imbalances are prevalent in ICU, dialysis, and malabsorptive populations. Despite advances in sweat sensing and infusion technologies, no existing system offers a closed-loop method to both monitor and regulate multiple mineral concentrations in real-time based on physiological data, particularly while enforcing safe inter-mineral ratios such as Zn:Cu and Ca:Mg.

Claim language that keeps you clear of industrial art

"…wherein the cartridge identifier is dynamically re-evaluated against a set of physiologic state rules and inter-cartridge conflict rules, and actuation of a second cartridge is suppressed when the conflict rules predict a harmful drug–drug or drug–state interaction."

"…the cartridge identifier further encodes a cumulative mg kg^{-1} ceiling and a chemical-class tag; the controller tracks patient weight and shuts off the pump when an extrapolated 30-minute projection would exceed the ceiling."

Industrial references lack the mg kg^{-1} element, the physiologic-state dependency, and the multi-cartridge conflict algebra—so they cannot anticipate these claims.

1. Block Diagram (left-hand column)

Label	Function
801	*Heartbeat Listener*: hardware timer that expects a “green-channel” ping from each micro-controller every 200 ms. Absence for >600 ms triggers fault flag **F_HEART**.
802	*Sensor-Fusion Consistency Engine*: validates that mutually-exclusive channels (e.g., *ICP_HTS* vs *MAP_NOREPI* after conflict-resolution) never issue opposing commands. Generates **F_CONTRA** faults.
803	*Actuator Feedback Verifier*: compares commanded vs. measured flow-rate, dose-rate, or electrical setting (closed-loop). Produces **F_DRIFT** events on deviation > 5 % persisting ≥ 3 s.
804	*Cyber-Security Monitor*: hardware root-of-trust + hash-chain that timestamps software images; any checksum drift → **F_AUTH**.

All four fault-sources send TTL-high lines to the *Safety Arbiter* (block **810**).

---

2. Safety Arbiter State Machine (centre panel)

State	Entry Conditions	Automatic Actions	Exit
S0 – Nominal	No active F_* flags	none	any F_* → appropriate degraded state
S1 – Graceful Degrade	Single **F_DRIFT OR F_CONTRA**	freezes the *affected* channel(s); elevates cross-channel guard-bands by 30 % (spec §4.3.2).	auto-return to S0 when flag clears for 30 s
S2 – Safe-Mode	≥2 concurrent *non-fatal* flags *or* one **F_HEART**	halts *all* non-life-support infusions; reverts ventilator, CRRT, vasopressors to clinician-preset backups; broadcasts CAN frame **0xDEAD_BEEF** to EMR.	manual override (§6.4) or power-cycle
S3 – Lock-out / Hard-Fail	Any **F_AUTH** *or* S2 lasting >60 s	open-drain relay cuts actuator power bus; LEDs flash 1 Hz; audible 2 kHz tone	system-board reset & signed firmware reload only

Transitions are shown with thick arrows, annotated by the particular F_* flag that provokes them; auto-recovery paths (dashed arrows) exist only to return S1→S0.

---

3. Interaction with Figures 5–7 (right-hand inset)

A miniature swim-lane traces the life-cycle of a sensor command that:

1. originates in the *Sensor Abstraction Layer* (Fig. 5),
2. passes through *Rule Compiler & Hierarchy Resolver* (Fig. 6),
3. is screened by the *Conflict-Group Handler* (Fig. 7),
4. and finally must obtain a **“GO” token** from the *Safety Arbiter* in S0 or S1 before energising any actuator.

Arbiter refusal in S2/S3 returns a *NACK* over the internal message bus, which the rule compiler logs with a UTC timestamp and drops the command.

---

4. Signal List & Timing Table

Signal	Source	Destination	Worst-case Latency
HB_OK	each µC	801	200 ms
F_DRIFT	803	810	20 ms
ARB_GO	810	actuator CAN node(s)	5 ms
ARB_NACK	810	rule-compiler	5 ms

5. Patent-Relevant Points

- Ensures *single-fault tolerance* by design (§112 support).
- Mapping of specific fault classes (**F_HEART**, **F_CONTRA**, etc.) to deterministic degradation states underpins the "predictable safe state" claim.
- Hardware-enforced power-bus cut in S3 satisfies IEC 60601-1 mechanical isolation requirements and distinguishes the invention from purely software watchdogs.

Figure 9 – Cryptographic Audit-Trail Backbone & Secure OTA Update Pipeline

Purpose
Figure 9 shows how every clinically-relevant event generated by the closed-loop platform is immutably logged, cryptographically chained, and synchronised with a secure off-site mirror—*while also enabling authenticated firmware/algorithm updates without ever violating the chain-of-custody*. This supports the enablement, written-description, and best-mode requirements for the claims that cover (i) tamper-evident decision logging and (ii) updateable yet safety-certified software.

1. Top-Level Data-Flow Diagram

Ref.	Module	Core Function
901	*Event Bus Tap*	Non-blocking snoop on the internal CAN/TSN bus; duplicates every message frame (sensor sample, rule decision, actuator command, fault code).
902	*Hash & Sign Engine*	SHA-256 stream hash updated every 100 ms; resulting digest signed with the device's ECDSA-P256 private key stored in a TPM.
903	*Local Ledger Store*	Circular NVMe partition; appends <counter‖timestamp‖frame‖sig> records; retains ≥72 h at 200 MB h^{-1}.
904	*Mirror-Sync Client*	When LTE/VPN available, bundles 1 MB blocks, adds Merkle root, pushes to remote ledger (§ 905) via gRPC/TLS 1.3.
905	*Cloud Ledger / Quorum Node*	Consortium Hyperledger Fabric instance run by hospital & manufacturer. Smart-contract enforces "write-once; sequential-counter" rule.
906	*Over-the-Air Update Server*	Hosts signed firmware images + SBOM. Publishes digest to Fabric; device accepts update only when ledger root matches.
907	*Dual-Bank Secure Bootloader*	Verifies ECDSA signature, writes to inactive flash bank, performs post-flash runtime self-test; swaps banks on next hard-reboot.
908	*TPM 2.0 Root-of-Trust*	Stores device key-pair, monotonic firmware-version counter, and revocation list for compromised update keys.

Arrows:

- **A** – *Event frames* (100 kB s^{-1}) → 901
- **B** – *Hashed blocks* → 903
- **C** – *Bundled blocks* → 904 → LTE → 905
- **D** – *Update manifest* (digest, version) ← 906 ← 905
- **E** – *Signed image* ↓ 907 (if manifest validated)

---

2. Timing & Storage Budget

Parameter	Value	Rationale
Frame replication latency	**≤ 2 ms**	Ensures logger cannot back-pressure real-time bus.
Local ledger endurance	**≥ 72 h**	Covers worst-case 48 h network outage + buffer.
Sync back-off	**Exponential (30 s→10 min)**	Minimises LTE cost under weak coverage.
Firmware image size	**≤ 32 MB**	Fits dual-bank flash on MCU variant B.

---

3. Fault & Attack Mitigations

Fault/Attack	Defence
Local disk corruption	Each 1 MB block has Merkle root + signature; invalid root rejected, re-requested from mirror.
Man-in-the-middle on LTE	TLS 1.3 + pinned hospital CA; ledger smart-contract refuses out-of-order counters.
Rollback attack	TPM monotonic counter compared against ledger “latest-version”; lower value update refused.
Key compromise	Revocation list (CRL) pulled hourly from 905; bootloader aborts if image signed by revoked key.

---

4. Interaction With Figures 5-8

- Figure 5 sensor layer writes raw samples → **901**
- Figure 6 rule-compiler decisions → **901**
- Figure 7 conflict-resolver suppressions logged as EVENT_TYPE=CONFLICT_RES frames.
- Figure 8 safety-arbiter state transitions (S1, S2, S3) logged with priority bit; entering **S3** forces immediate sync (even on battery).

---

5. Patent-Relevant Highlights

1. **Chained audit entries** ensure *non-repudiation* of every autonomous action—key for regulatory submissions (21 CFR § 820.70(i)).

2. **Mutual attestation** between device and Fabric ledger allows *over-the-air updates* **without breaking safety certification**, satisfying the "adaptive yet verifiable" claim element.
3. **Dual-bank architecture** provides *fail-operational rollback*—device can boot last-known-good image if self-test fails, supporting the "predictable safe state on update failure" limitation.

Figure 10 – Clinician-Override Interface & Escalation Ladder

Purpose
Figure 10 documents the *human-in-the-loop safety layer* that sits on top of the autonomous rule engine described in Figures 5-9. It discloses exactly **how a bedside nurse, respiratory therapist, or attending can temporarily override or permanently re-authorise any closed-loop channel**, while ensuring (i) the system remains aware of the override, (ii) the audit-trail is preserved, and (iii) alarm fatigue is minimised via a strictly timed escalation ladder. These elements support the claim set on *role-based override, bounded-duration silencing, and automatic re-arm with cryptographic attribution*.

---

1. Physical & Logical Components

Ref.	Component	Function
1001	*Tri-colour E-Ink Status Tile*	Always-on display embedded in the front cover of each node; shows current channel state (RUN, OVERRIDE-T, LOCK-S3). Low power → remains visible even on battery cut-over.
1002	*Capacitive "Confirm / Silence" Dial*	Single rotary-push control. Clockwise = extend override in 5 min quanta (max 30 min per credential); push-hold 2 s = "Acknowledge & Silence" for 120 s.
1003	*BLE / NFC Badge Reader*	Reads SHA-256 hash of clinician ID from existing hospital badges. Keyed-hash MAC prevents replay.
1004	*Role-Based Access Token Service (RBATS)*	Runs on the node; maps badge hash → role (RN-I, RT, MD-ICU, MD-Attending) + scope (channels this caregiver may override) using a signed policy bundle refreshed hourly from the Fabric ledger (§ 905).
1005	*Policy Decision Point (PDP)*	Evaluates override request against: role scope, current system safety-state, interlock rules (Fig. 7 conflicts), timer limits.
1006	*Override Scheduler / Re-Arm Timer*	If PDP grants, places channel in OVERRIDE-T with expiry T_now + Δt; emits countdown beeps last 30 s; auto-re-arms channel at expiry.
1007	*Escalation Engine*	On unacknowledged high-severity alert, pages ladder: **1** bedside tile & nurse phone (30 s); **2** charge nurse (90 s); **3** attending & central command (3 min).
1008	*Audit Emitter*	Logs OVERRIDE_REQUEST, GRANT, DENY, AUTO_REARM frames to the hash-and-sign engine (Figure 9 § 902).
1009	*Remote Monitor Dashboard*	WebSocket view that mirrors tile colour/state and remaining override time across all beds; allows authorised override *termination* but *never initiation* (to meet "local positive control" requirement).

---

2. Override Flow (Numbered on Figure)

1. **Badge Tap** → 1003 reads and forwards badge MAC to RBATS (1004).

2. **Dial Action** (rotate or press) captured by 1002 → intent (SILENCE, OVERRIDE) sent to PDP (1005).
3. **PDP Evaluation** – checks:
    - channel is *not* in SAFE-STATE S3;
    - requested $\Delta t \leq$ role limit (RN-I: 10 min, RT: 15 min, MD-ICU: 30 min);
    - no active antagonist loop (from Figure 7) would be simultaneously overridden.
4. **Grant / Deny** – result returned to 1002 (haptic click & colour change) and to 1006.
5. **Scheduler** 1006 starts countdown; at expiry auto-re-arms and notifies 1008.
6. **Audit** 1008 streams signed record to Fabric ledger (Figure 9).
7. **Escalation** 1007 continues to run in parallel; if alert persists beyond override window, ladder proceeds.

---

3. Timing & Human-Factors Constraints

Metric	Target	Justification
Override decision latency	**< 200 ms**	Feels instantaneous to user; avoids double-tap errors.
Audible reminder cadence	1 beep min^{-1} (0-5 min), 4 beeps min^{-1} (last 30 s)	Proven in alarm-fatigue literature to balance notice vs. nuisance.
Colour coding	*Green* = RUN; *Amber* = OVERRIDE-T; *Red* = LOCK-S3	Consistent with ISO 60601-1-8.

---

4. Safety & Security Mitigations

Threat	Counter-measure
Stolen badge used to override	RBATS tokens expire after 8 h *since last LDAP heartbeat*; device cross-checks with hospital LDAP every 15 min.
Infinite silence via repeated overrides	Monotonic counter per shift; after 3 consecutive overrides without MD review, PDP forces attending approval.
Unlogged override via network	Only *initiation* accepted from physical dial + badge; remote dashboard can *cancel* only.
Display blackout	E-Ink retains last state without power; watchdog resets tile driver after 3 s blank detection.

---

5. Claim Support Highlights

- **Bounded override with automatic re-arm** – claim element 23(c).
- **Role-based time caps** – claim element 24(b)(iii).
- **Cryptographically attributable clinician action** – element 25.
- **Alarm-fatigue mitigation via progressive escalation & colour persistence** – element 26.

FIG. 2 – Closed-Loop Apex Controller as a clean, patent-style line drawing.
It depicts the central APEX CONTROLLER CPU (230) containing the real-time Rule Engine (210) and

Safety Overrides layer (220).
Sensor data arrives on the left, flows up to the Communications Bus (240), and is logged by the Data Manager (230→).
Commands leave via a Subcontroller Bus feeding representative subordinate loops—Ventilation (242), Hemodynamics (244), Neuro, etc. (246)—which in turn drive actuators.

Let me know when you're ready for FIG. 3—or if you'd like any edits to this one first.

Here's the schematic database drawing for **FIG. 3 – "Factor-Registry Relational Schema."**
Let me know if you'd like tweaks (extra columns, different layout, added notes) or we can move on to FIG. 4.

Here's **FIG. 4 – "Arbitration Engine & Real-Time Conflict-Resolution Flow."**
It lays out how factor triggers, cross-channel rules and safety guards converge through priority checks, mutual-exclusion gates and synergy evaluation before issuing a single, conflict-free actuator command (with logging).

FIG. 5 – Hierarchical Failsafe & Watchdog States

Download the full-resolution drawing

This figure illustrates the progressive escalation ladder the system follows when safety conditions deteriorate. Starting at **L1 Factor Local Guard**, each higher tier provides a broader supervisory scope—culminating in **L5 Manual Clinician Override**—while the left-hand "FALLBACK" arrow depicts automatic reversion to the lowest safe state once correction is achieved.

Here's the sixth drawing for the application — **FIG. 6: Sensor-Actuator Command Matrix (S × A Matrix)** — supplied as a patent-style black-and-white line illustration.
Download FIG-6

FIG. 7 – "Rule-Execution Priority Ladder."

This drawing visualizes the six hierarchical tiers the controller uses when deciding which rule fires first—from absolute safety overrides at the top down to non-blocking logging operations at the bottom. Let me know when you're ready for the next figure—or if you'd like any tweaks to this one.

Here is **FIG. 8 – Fail-Safe Watchdog Timers & Redundancy Paths**, a patent-style black-and-white line drawing that shows:

- the primary **Controller** receiving sensor inputs;
- dual **Redundant Microcontrollers** that shadow the controller and can seize control on fault;
- a hardware **Watchdog Timer** that supervises both paths and triggers switchover;
- the normal **Actuator Path** and an electrically isolated **Fallback Actuator Path** engaged on watchdog timeout;
- clearly directed arrows that illustrate data and control-flow between blocks.

FIG. 9 – Data Provenance & Audit-Log Chain

What it shows

Ref. No.	Element	Function
902	Sensor array	Generates primary clinical datapoints (glucose, ion-Ca, IL-6, etc.).
904	Edge data-collector MCU	Time-stamps + signs packets; rejects out-of-band frames.
906	*Immutable log blockchain ledger*	Appends each signed packet as a block; embeds SHA-256 hash of the previous block to form an audit-proof chain.
908	Regulatory reporting node	Read-only replica that fulfils §820.180(e) & ISO 13485 traceability requirements; exports HL7 FHIR bundles on demand.
—	Clinician query interface (dashed)	Read-only API; prevents tampering yet permits "explain" queries for event reconstruction.

Purpose

- Locks raw sensor data, control decisions, and overrides into an append-only ledger so the system passes the FDA "immutable provenance" test and the EU MDR post-market surveillance rules.
- Provides cryptographic proof that no record in the treatment hierarchy was altered after-the-fact—crucial when cross-channel arbitration (FIG. 4) or watchdog overrides (FIG. 8) are litigated.
- Supports later machine-learning model re-training with a verifiable lineage back to the original bedside events.

Here's **FIG. 10 – Model Re-training & Validation Pipeline**.
The drawing depicts the end-to-end data flow that guards every new model release:

call-out	element	key duties
1002	**Raw Ledger**	immutable append-only log of sensor events, clinician edits, & outcomes (see FIG. 9 provenance chain).
1004	**Feature Store**	real-time materialisation of vetted features; enforces schema & drift detection before training.

call-out	element	key duties
1006	**Offline Training Cluster**	GPU/TPU farm that retrains candidate models using only features that passed gate 1004.
1008	**Validation Harness**	battery of synthetic adversarial cases + 30-day hold-out set; pushes results to sandbox 1010.
1010	**Regulatory Sandbox**	air-gapped environment for reproducibility, bias audit, and hierarchical-logic conformance checks.
1012	**Signed Model Artifact** *(implicit in the dashed path)*	cryptographically signed once checkpoints 1008 & 1010 succeed.
1014	**Deployment Gate (Canary)**	staged rollout with live-shadow scoring; monitors harm-severity metrics before fleet promotion.

Solid arrows show the primary data path; dashed arrows indicate feedback / audit loops that can halt promotion if any safety envelope (FIG. 5) or watchdog sentinel (FIG. 8) trips.

Download: FIG-10 line drawing

Closed-Loop Patient-Safety Arbitration System

1. Cross-Reference to Related Applications

This application claims priority to any and all U.S. and foreign provisional applications filed on or before the date hereof that disclose subject matter common to the present disclosure, including the spreadsheet-encoded hierarchy first transmitted on *[date]* under attorney docket **ICU-HIER-001-P**.

2. Field of the Invention

The invention relates to autonomous and semi-autonomous physiological control systems in critical-care medicine. More particularly, it concerns a data model and arbitration engine that coordinate multiple closed-loop drug-delivery and device-control “loops” competing for shared patient actuators.

3. Background

Existing single-parameter closed loops (e.g., insulin PIDs) cannot be safely aggregated. Manual protocols attempt to order interventions but break down at machine speed. Current rule engines lack: (i) formal dependency representation; (ii) deterministic tie-breaking; (iii) compile-time validation; and (iv) an auditable explanation layer.

4. Summary of the Disclosure

A **relational representation** encodes each sensor loop as a row having **fifteen mandatory columns** (Table 1). At run-time, rows are converted into a **directed acyclic graph (DAG)** whose edges encode precedence (priority_over), mutual exclusion, synergy scheduling and gating requirements. A **numerical risk score** further ranks loops, and a **per-actuator arbitration queue** executes the highest-priority compatible loop each control cycle. The system self-validates, logs every arbitration decision, and exposes a human fail-safe override.

5. Loop-Encoding Schema

column	type / domain	description
id	string (unique)	canonical row identifier
label	string	human-readable name
category	{Hemodynamic, Renal, …}	clinical grouping
organ_system	{Cardiac, Neurologic, …}	primary target system
harm_severity	integer 1-9	FDA ISO-14971 derived
time_to_harm	enum {minutes, hours, days}	worst-case onset
reversibility_window	enum {short, moderate, long}	median time until damage irreversible
conflict_group	string	physical actuator namespace (e.g., *VENTILATOR*, *IV_PUMP_1*)
sensor_modality	string	hardware class for licensing claims
cross_channel_rules	free text	clinical rule snippet
priority_over	CSV of ids	hard precedence edges
mutually_exclusive	CSV	symmetric block edges
synergy_with	CSV	soft co-schedule edges
requires_ok	CSV	gating dependencies
id (trailer)	duplicate key for import stability	

Compile-time validators assert: (a) id uniqueness, (b) non-empty conflict_group, (c) priority_over graph is acyclic, (d) mutually_exclusive edges are symmetric, (e) all references resolve.

6. Numerical Risk Engine

For every loop *L* the system calculates

$\text{Risk}(L) = (\text{harm\_severity} \times \tau[\text{time\_to\_harm}]) / \omega[\text{reversibility\_window}]$
where τ and ω are constant lookup tables (e.g., minutes = 1.0, hours = 0.5, days = 0.1; short = 0.75, moderate = 1.0, long = 1.5). The score seeds a **priority queue P^c** per conflict_group *c*.

7. Graph Construction

At start-up the engine:

1. **Canonicalises duplicates** by hashing {label,organ_system} and set-unioning list fields while preserving provenance.
2. Builds a **directed graph G(V,E)** where V = loops and E comprises:
    - hard precedence e_1 = priority_over
    - gating e_2 = requires_ok (edge type = *gate*)
    - mutual-exclusion stored bidirectionally; enforced at schedule time
    - synergy stored bidirectionally with co-schedule flag Δt
3. Performs **topological sort** of precedence edges inside each conflict group. Cycles raise a compile-time error.

8. Arbitration Algorithm

For each control cycle *t* and each conflict_group *c*:

```
1. $P^c \leftarrow$ all enabled loops in group c
2. discard any L where $\exists M$ s.t. $(L,M) \in$ mutually_exclusive and M is running
3. discard any L with unsatisfied requires_ok gate
4. sort $P^c$ by  (Risk desc, topo_rank asc, timestamp asc)
5. execute head($P^c$)
6. if head(L) has synergy_with S and $S \in P^c$ within $\Delta t \rightarrow$ co-schedule
```

A **manual supervisor flag** can inject a hard block that bypasses steps 2-6.

9. Explainability Layer

Every decision logs a JSON blob:

```
{
 "timestamp": 1685570400,
 "group": "IV_PUMP_1",
 "winner": "ANTI_XA",
 "losers": ["HEPARIN_PROTAMINE"],
 "risk": {"ANTI_XA":17.5,"HEPARIN_PROTAMINE":15.0},
 "edge": "priority_over"
}
```

The log meets FDA draft guidance on ML transparency.

10. Fail-Safe Override

A clinical_supervisor channel writes to a protected register OVERRIDE[id] ∈ {BLOCK, FORCE}. BLOCK masks the row pre-graph; FORCE elevates the row above all precedence edges for the next cycle only, then reverts.

11. Example Embodiment – Anti-Xa / Protamine

ANTI_XA (risk 17.5) has priority_over=HEPARIN_PROTAMINE; *HEPARIN_PROTAMINE* has a gating requires_ok=ANTI_XA. When anti-Xa > 0.7 IU the loop's actuator is the **protamine pump** (conflict_group=PUMP_PROT). The engine topologically ranks *ANTI_XA* first and the gate prevents *HEPARIN_PROTAMINE* from running until anti-Xa ≤ 0.7 IU.

12. Hardware & Deployment

- Sensors: sweat-based nano-FETs, microneedle ISEs, optical spectrophotometers, etc.
- Controllers: STM32-class MCU for bedside unit or containerised micro-service.
- Graph depth limited to 1024 nodes to meet real-time deadline @ 100 Hz scan.

13. Regulatory Mapping

schema column	ISO-14971	IEC 62304	FDA 'Good ML Practice'
harm_severity	Hazard analysis Table A.3	-	Risk management artefact
reversibility_window	Severity class	-	-
explainability log	-	5.8 Traceability	Transparency
compile-time checks	7.3 Verification	5.4 Software unit test	Verification

14. Advantages Over Prior Art

1. Single canonical table drives *all* safety layers.
2. Numeric + graph tie-breakers yield deterministic behaviour under overload.
3. Compile-time proofs eliminate silent precedence cycles.
4. Extensible to any actuator class via conflict_group indirection.

15. Concluding Remarks

The foregoing specification, including the examples, enables a person skilled in the art to make and use the invention and sets out the best mode presently contemplated. Variations remain within the scope of the appended claims to be drafted at non-prosecution stage.

Figure 5 — Entity-Relationship (ER) Diagram

[FIG. 5]

This figure illustrates the relational structure of the closed-loop factor database, including primary and foreign-key relationships between the **Factors**, **Rules**, **Channels**, and **Cross-Channel Rules** tables. Crow's-foot notation is used to demonstrate one-to-many joins, while a shaded overlay highlights the composite id key that suppresses duplicate-row collisions.

Figure 6 — Sensor Event Processing Sequence Diagram

A UML sequence diagram illustrating the real-time path from a sensor firing (e.g., sweat nano-LPS strip detecting endotoxin) through the decision-engine tiers (Filtering, Arbitration, Therapy Mapping, Guard Rails) to the final actuation of compatible drug pumps. The diagram highlights asynchronous micro-services, the arbitration lock window, cross-channel conflict checks, and the safety-watchdog interrupts that can abort or roll back the sequence if a higher-priority harm loop pre-empts the request.

CLOSED-LOOP PATIENT-SAFETY ARBITRATION SYSTEM

(Revised Specification with FIGS. 1-10)

1. Cross-Reference to Related Applications

This application claims priority to all U.S. and foreign provisional applications filed on or before the date hereof that disclose subject matter common to the present disclosure, including the spreadsheet-encoded hierarchy first transmitted on **[DATE]** under attorney docket **ICU-HIER-001-P** and the line-drawing figures (FIGS. 1-10) generated on **[TODAY'S DATE]**.

---

2. Field of the Invention

The invention relates to autonomous and semi-autonomous physiological control systems in critical-care medicine. More particularly, it concerns a relational data model and arbitration engine that coordinate multiple closed-loop drug-delivery and device-control "loops" competing for shared patient actuators.

---

3. Background

Conventional single-parameter closed loops (e.g., insulin PID controllers) cannot be naively aggregated; emergent conflicts between drug pumps, ventilator settings, and hemodynamic supports can jeopardise patient safety in milliseconds—well inside a clinician's reaction time. Existing rule engines lack:

- (i) **formal dependency representation**,
- (ii) **deterministic tie-breaking**,
- (iii) **compile-time graph validation**, and
- (iv) an **auditable explanation layer** that regulators can inspect.

These gaps motivate the present disclosure.

---

4. Summary of the Disclosure

A **relational representation** encodes every sensor-driven control loop as a canonical row with fifteen mandatory columns (Table 1, §5). At run-time the rows are canonicalised into a **directed acyclic graph (DAG)** whose edges capture precedence, gating, mutual-exclusion and synergy semantics.
A **numerical risk score** feeds one priority queue per physical **conflict group** (e.g., *VENTILATOR*, *IV_PUMP_1*). Each 10 ms control cycle the engine selects the top-ranked, mutually compatible loop in every queue and emits actuation commands.

Key safety layers are illustrated in:

---

5. Loop-Encoding Schema

column	domain	description
id	string (unique)	canonical identifier
label	string	human-readable name
category	enum {Hemodynamic, Renal, …}	clinical grouping
organ_system	enum {Cardiac, Neurologic, …}	primary system
harm_severity	integer 1–9	ISO-14971 derived
time_to_harm	{minutes, hours, days}	worst-case onset
reversibility_window	{short, moderate, long}	time until damage becomes irreversible
conflict_group	string	physical actuator namespace
sensor_modality	string	hardware class
cross_channel_rules	free text	clinical rule snippet
priority_over	CSV of ids	hard precedence edges
mutually_exclusive	CSV	symmetric block edges
synergy_with	CSV	co-schedule edges
requires_ok	CSV	gating dependencies

column	domain	description
id (trailer)	duplicate key for import stability	

Compile-time validators (FIG. 4) assert:
(a) id uniqueness, (b) non-empty conflict_group, (c) acyclic priority_over, (d) symmetric mutually_exclusive, (e) all references resolve.

6. Numerical Risk Engine

For each loop *L*:

$$\mathrm{Risk}(L) = (\text{harm\_severity} \times \tau[\text{time\_to\_harm}]) / \omega[\text{reversibility\_window}]$$

Lookup tables τ and ω are configurable (minutes = 1.0; hours = 0.5; days = 0.1;
short = 0.75; moderate = 1.0; long = 1.5).
The score seeds a **priority queue P^c** for every conflict_group *c*.

7. Graph Construction

Startup procedure (FIG. 4):

1. **Canonicalise duplicates** (hash {label, organ_system}) while union-merging list fields.
2. Build **graph G(V,E)**:
    - precedence edge =priority_over
    - gating edge =requires_ok
    - mutual-exclusion = bidirectional block
    - synergy edge = bidirectional with Δt window
3. **Topologically sort** precedence edges inside each conflict group; cycles raise compile-time error.

8. Arbitration Algorithm

For each cycle *t* and conflict group *c* (see flow in FIG. 7):

1. $P^c \leftarrow$ enabled loops in group c
2. drop L with running mutually_exclusive peer
3. drop L whose requires_ok gates are false
4. sort P^c by (Risk↓, topo_rank↑, timestamp↑)
5. execute head(P^c)
6. if head has synergy_with S inside Δt → co-schedule

A clinician may set OVERRIDE[id] ∈ {BLOCK, FORCE} (§10).

9. Explainability Layer

Every arbitration outcome emits a signed JSON (see §9 original; path unchanged), persisted to the **Provenance Ledger** in FIG. 9. Regulators obtain deterministic replay.

10. Fail-Safe Override

- BLOCK masks a row pre-graph until cleared.
- FORCE elevates a row above precedence for one cycle, then auto-reverts.

11. Watch-Dog Sentinel Table (FIG. 8)

FIG. 8 tabulates hardware-level sentinel threads (e.g., **CPU-WDT**, **CAN-BUS-CRC**, **ADC-CLIP**). Each sentinel maps to: *(i)* monitored resource, *(ii)* timeout, *(iii)* mitigation (pump hard-stop, alarm, or power-cut), and *(iv)* restart policy. Sentinels run outside the main scheduler and can pre-empt any loop.

12. Model-Lifecycle Safety (FIG. 10)

FIG. 10 details the offline/online ML pipeline:

- **Raw Ledger 1002 ⟶ Feature Store 1004**
- **Training Cluster 1006 ⟶ Validation Harness 1008**
- **Regulatory Sandbox 1010** produces **Signed Model 1012**
- **Canary Deployment 1014** with live shadow-scoring.

Failures at any stage raise a fuse that disables promotion.

13. Hardware & Deployment

- Sensors: sweat nano-FETs, microneedle ISEs, optical spectrophotometers.
- Controllers: STM32-H7 MCU (bedside) or containerised micro-service (cloud).
- Real-time deadline: **100 Hz** scan; max **1024 nodes** per graph.

14. Regulatory Mapping

schema element	ISO-14971	IEC 62304	FDA "Good ML Practice"
harm_severity	Hazard analysis A.3	–	Risk artefact
reversibility_window	Severity class	–	–
provenance ledger (FIG. 9)	–	5.8 Traceability	Transparency
compile-time proofs	7.3 Verification	5.4 Unit tests	Verification
ML pipeline (FIG. 10)	Risk control	5.1 Software dev.	Total-product-lifecycle

---

15. Example Embodiment – Anti-Xa / Protamine

Identical to §11 in the prior draft; now traced in the FIG. 9 ledger and guarded by FIG. 8 sentinels.

---

16. Advantages Over Prior Art

1. **Single canonical table** feeds every safety layer.
2. **Risk × graph** tie-breakers give deterministic behavior under overload.
3. **Compile-time proofs** eliminate silent precedence cycles.
4. **Sentinel & ML pipelines** (FIGS. 8-10) extend safety to hardware faults and model drift.
5. **Cryptographic provenance** (FIG. 9) enables FDA/EMA reproducibility audits.

§17 — Non-Medical and Industrial Embodiments (add after §14 "Advantages Over Prior Art")

Generalisation of Terminology. Throughout the foregoing description the terms *"patient,"* *"physiological sensor,"* *"drug-delivery pump,"* and the like are used for clarity in a critical-care context. Unless expressly stated otherwise, each such term **shall be construed broadly** to encompass any cyber-physical process in which multiple closed-loop controllers compete for one or more shared actuators.

Medical Term (illustrative)	Generic/Industrial Counterpart	Illustrative Examples
Physiological **sensor**	Process or machine **sensor**	Temperature probe, torque transducer, pH electrode, gas chromatograph
Therapeutic **actuator** / IV pump	**Final-control element**	Steam valve, VFD-driven motor, feeder auger, dosing pump
Clinical harm severity	**Process-hazard severity**	Product scrap cost, environmental breach, worker safety incident

Medical Term (illustrative)	Generic/Industrial Counterpart	Illustrative Examples
Time-to-harm	**Time-to-fault**	Seconds to exceed set-point, minutes until batch spoilage
Reversibility window	**Recoverability window**	Downtime before irreversible catalyst deactivation
Conflict group	**Resource namespace**	Conveyor lane, robot end-effector, boiler header
Manual supervisor override	**Operator or PLC override**	Maintenance bypass, e-stop, regulatory interlock

17.1 Industrial Control Loop Encoding

Every industrial control loop (e.g., a temperature PID, level controller, or quality-inspection reject gate) is encoded **identically** to the fifteen-column schema of Table 1:

- **category** might take values such as *Thermal, Flow, Motion, Quality*.
- **organ_system** is replaced by **process_unit**—the portion of the plant primarily affected (reactor train, packaging line, etc.).
- **harm_severity, time_to_harm, reversibility_window** map to process-hazard analyses (e.g., SIL or LOPA scoring).
- **conflict_group** namespaces shared actuators such as a diverter gate or a shared CIP skid.
- **Edge-defining fields** (priority_over, mutually_exclusive, synergy_with, requires_ok) are populated exactly as in the medical embodiment, yielding the same compile-time proofs of acyclicity and symmetric exclusion.

17.2 Industrial Arbitration Cycle

During operation of a manufacturing plant, the run-time algorithm of §8 executes **per conflict group** just as it does per IV-pump in the ICU embodiment. For example, in a bottling line:

1. A *fill-level sensor loop* and a *foam-suppression loop* may contend for the same pneumatic valve (**conflict_group = FILL_VALVE**).
2. The *foam loop* carries a higher harm_severity (product waste) but a longer time_to_harm; the risk engine ranks them deterministically.
3. A *pasteurisation loop* may list the *foam loop* in requires_ok, preventing hot water injection until foam is under control.

17.3 Regulatory and Safety Mapping

ISO-14971 and *FDA Good-ML* columns map naturally to **IEC 61511 (SIL)**, **ISO 13849** or **IEC 62061** for machinery safety; compile-time checks (§5 validators) satisfy software verification clauses of **IEC 61508-3**.

Scope Statement (to be inserted in concluding remarks):
The invention is **not limited** to healthcare or to human or veterinary patients. All embodiments, features and advantages described herein apply *mutatis mutandis* to industrial automation, manufacturing, food-processing, aerospace, autonomous vehicles, robotics, power-generation and any other domain in which

multiple feedback controllers vie for common actuation resources. Accordingly, references to “patient,” “drug,” “clinician” or similar medical vocabulary shall be interpreted as exemplary and non-restrictive.

---

17. Concluding Remarks

The foregoing specification—including FIGS. 1-10—enables a person skilled in the art to make and use the invention and sets out the best mode presently contemplated. Modifications, such as alternative sensor modalities or additional actuator namespaces, remain within the scope of the claims to be drafted in a non-prosecution stage.

LIST OF NEW FIGURES & DOWNLOAD LINKS

Fig.	Title	Download
8	Watch-Dog Sentinel Reference Table	FIG-8
9	Cryptographic Data-Provenance Ledger	FIG-9
10	Model Re-training & Validation Pipeline	FIG-10

Figures 1-7 remain as previously filed; files are unchanged.

Done. Let me know if you’d like wording tweaks, claim skeletons, or a clerical header (37 C.F.R. §1.77) for formal filing.

You said:

i want the place and figure descriptions so i can paste them in

ChatGPT said:

Thought for 5 seconds

Below is a ready-to-paste **Figure list**.
For each item you get (a) the *in-text placeholder* to drop into the body, and (b) the *formal caption* that goes beneath the drawing in the drawings section.